

Serveur Académique Lausannois SERVAL serval.unil.ch

Author Manuscript

Faculty of Biology and Medicine Publication

This paper has been peer-reviewed but does not include the final publisher proof-corrections or journal pagination.

Published in final edited form as:

Title: Applications of MALDI-TOF mass spectrometry in clinical diagnostic microbiology.

Authors: Croxatto A, Prod'hom G, Greub G

Journal: FEMS microbiology reviews

Year: 2012 Mar

Volume: 36

Issue: 2

Pages: 380-407

DOI: 10.1111/j.1574-6976.2011.00298.x

In the absence of a copyright statement, users should assume that standard copyright protection applies, unless the article contains an explicit statement to the contrary. In case of doubt, contact the journal publisher to verify the copyright status of an article.

1
2
3
4 1 **Applications of MALDI-TOF mass spectrometry in clinical**
5
6
7 2 **diagnostic microbiology**
8

9
10 3 Antony Croxatto, Guy Prod'hom & Gilbert Greub*
11

12 4
13
14 5 Institute of Microbiology, University Hospital Center and University of Lausanne, Lausanne,
15
16 6 Switzerland
17

18
19 7
20

21 8
22

23
24 9
25

26 10 *Correspondence
27

28 11 Gilbert Greub, MD PhD
29

30 12 Institute of Microbiology
31

32
33 13 University Hospital Center and University of Lausanne
34

35 14 1011 Lausanne
36

37
38 15 SWITZERLAND
39

40 16 Phone: (00) 41 21 314 49 79
41

42 17 Fax: (00) 41 21 314 40 60
43

44
45 18 Email: gilbert.greub@chuv.ch
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 **Abstract**

2 Until recently, microbial identification in clinical diagnostic laboratories has mainly relied on
3 conventional phenotypic and gene sequencing identification techniques. The development of
4 Matrix-Assisted Laser Desorption Ionization Time-Of-Flight mass spectrometry (MALDI-
5 TOF MS) devices has revolutionized the routine identification of microorganisms in clinical
6 microbiology laboratories by introducing an easy, rapid, high throughput, low-cost and
7 efficient identification technique. This technology has been adapted to the constraint of
8 clinical diagnostic laboratories and has the potential to replace and/or complement
9 conventional identification techniques for both bacterial and fungal strains. Using
10 standardized procedures, the resolution of MALDI-TOF MS allows accurate identification at
11 the species level of most Gram-positive and Gram-negative bacterial strains with the
12 exception of a few difficult strains that require more attention and further development of the
13
14 and much quicker than conventional techniques. Recent studies have shown that MALDI-
15 TOF MS has also the potential to accurately identify filamentous fungi and dermatophytes,
16 providing that specific standardized procedures are established for these microorganisms.
17 Moreover, MALDI-TOF MS has been used successfully for microbial typing and
18 identification at the subspecies level, demonstrating that this technology is a potential efficient
19 tool for epidemiological studies and for taxonomical classification.

1
2
3 1
4
5
6
7 2

Introduction

3 The Matrix-Assisted Laser Desorption Ionization Time-Of-Flight mass spectrometry
4 (MALDI-TOF MS) is a rapid, accurate and cost-effective method of microbial
5 characterization and identification. This technology generates characteristic mass spectral
6 fingerprints, that are unique signatures for each microorganism and are thus ideal for an
7 accurate microbial identification at the genus and species levels, and has a potential to be used
8 for strain typing and identification.

9 Mass spectrometry has been used for several decades in chemistry but it was in 1975 that
10 Anhalt and Fenselau (Anhalt & Fenselau, 1975) proposed for the first time that bacterial
11 characterization could be achieved using this technique. They noticed that unique mass
12 spectra were produced from bacterial extracts of different genera and of different species. In
13 the 1980s, the development of desorption/ionization techniques such as plasma desorption
14 (PD), laser desorption (LD) and fast atom bombardment (FAB) allowed the generation of
15 molecular biomarker ions from microorganisms leading to bacterial profiling (Heller, *et al.*,
16 1987, Platt, *et al.*, 1988). In early experiments, only biomarker molecules of low mass
17 molecular masses such as bacterial lipids were analysed (Shah & Collins, 1980, Heller, *et al.*,
18 1988) since the processes used for the ionization of biomolecules were too energy rich to
19 avoid unpredictable analyte decomposition. The evolution of soft ionization techniques such
20 as matrix-assisted laser desorption ionization (MALDI) and electrospray ionization (ESI)
21 developed in the late 1980s (Tanaka & Fenn, 2002) made possible analysis by mass
22 spectrometry of large biomolecules such as intact proteins. Several groups (Cain, *et al.*, 1994,
23 Girault, *et al.*, 1996, Liang, *et al.*, 1996) demonstrated that MALDI-TOF could be used to
24 produce protein profiles following cellular extraction and purification. However, Holland *et*

1
2
3 1 *al.* (Holland, *et al.*, 1996) reported for the first time in 1996 that MALDI-TOF spectral
4
5
6 2 fingerprints could be obtained from whole bacterial cells without pre-treatment before the MS
7
8 3 analysis. This approach was then used to identify bacteria at the genus and species levels by
9
10 4 multiple research teams (Claydon, *et al.*, 1996, Krishnamurthy & Ross, 1996, Haag, *et al.*,
11
12 5 1998, Pribil & Fenselau, 2005, Pignone, *et al.*, 2006, Vargha, *et al.*, 2006). Since the late
13
14 6 1990s, the success of this technique for the rapid identification of bacteria but also fungi and
15
16 7 yeast was demonstrated by an impressive exponential increase in the number of publications
17
18 8 concerning MALDI-TOF identification of microorganisms.
19
20
21

22
23 9 MALDI-TOF MS has been used to characterize a wide variety of microorganisms including
24
25 10 bacteria, fungi, and viruses (Giebel, *et al.*, 2010). The capability of MALDI-TOF to rapidly
26
27 11 characterize microorganisms favours its potential applications in multiple areas including
28
29 12 medical diagnostics, biodefense, environmental monitoring, and food quality control.
30
31 13 MALDI-TOF MS is suitable for high-throughput and rapid microbial identification at low
32
33 14 costs and is an alternative for conventional laboratory biochemical and molecular
34
35 15 identification systems.
36
37
38
39

40 16 In this review, we will first present the technical background of the MALDI-TOF MS method
41
42 17 including sample preparation, mass spectrometry, bioinformatics analysis of fingerprint
43
44 18 spectra and their comparison with databases for microorganism identification. We will then
45
46 19 present the application of MALDI-TOF MS microbial identification from bacteria and fungi
47
48 20 isolates and directly from clinical samples. We will then address the important issues of
49
50 21 quality control, maintenance, time-to results and cost effectiveness. Finally, we will discuss
51
52 22 the use of MALDI-TOF MS for additional applications such as microbial taxonomy, typing
53
54 23 and identification of virulence factors (Bizzini & Greub, 2010, Murray, 2010).
55
56
57
58
59
60

1 **Technique**

2 A mass spectrometer is composed of three functional units, (1) an ion source to ionize and
3 transfer sample molecules ions into a gas phase, (2) a mass analyser that separate ions
4 according to their mass-to-charge ratio (m/z), and (3) a detection device to monitor separated
5 ions. Several ionization methods have been developed including PD, FAB, chemical
6 ionization (CI), atmospheric pressure chemical ionization (APCI), electrospray (ESI), LD, and
7 matrix-assisted laser desorption/ionisation (MALDI). The method of ionization is determined
8 according to the nature of the sample and the goal of the MS analysis, but ESI and MALDI
9 are soft ionization techniques that allow ionization and vaporization of large non-volatile
10 biomolecules such as intact proteins (Emonet, *et al.*, 2010). In contrary to ESI, MALDI
11 generates mostly singly charged ions and thus MALDI derived spectra may include larger
12 numbers of proteins. Laser desorption has been successfully coupled to several kinds of mass
13 analysers to characterize microorganisms such as time of flight (TOF) (Lay, 2001), Fourier
14 transform ion cyclotron resonance (Ho & Fenselau, 1998), quadrupole-TOF (She, *et al.*, 2001)
15 and quadrupole ion trap (Meetani, *et al.*, 2007). The various operative modes of the different
16 mass analysers confer strengths and weaknesses in their performance characterized by mass
17 accuracy, resolution, mass range, sensitivity, scan speed and cost (Table S1) (Jonsson, 2001,
18 Aebersold & Mann, 2003, Domon & Aebersold, 2006, Graham, *et al.*, 2007). The
19 performance of mass analysers can be improved by combining and/or summing the
20 advantages of one sort of analyser (tandem MS) or of different analysers (hybrid MS) through
21 the development of multistage instruments such as hybrid quadrupole time of flight (Q-Q-
22 TOF), tandem time of flight (TOF-TOF) and triple quadrupole (Domon & Aebersold, 2006).
23 Overall, the required performance expected form a mass analyser depends on the type of
24 sample to be analysed (complex/simple mixtures, proteins, peptides, lipids, polysaccharides)

1 and the ultimate goal of the analysis (quantification, protein identification, microorganism
2 identification, biotyping).

3 Time of flight mass analysers (Cotter, 1997) have been used for intact microorganisms
4 detection for many years (Heller, *et al.*, 1987) because they are suited for interfacing with
5 pulse laser ionization and offer the possibility of rapid analysis and miniaturization.

6 In MALDI analysis, samples are prepared by mixing the samples with a matrix which results
7 in the crystallisation of the sample within the matrix. The matrix is composed of small acid
8 molecules that have a strong optical absorption in the range of the laser wavelength used. The
9 matrix composition varies according to the biomolecule to be analysed and the type of laser
10 used (Fenselau & Demirev, 2001). The most frequently used matrices are 2,5-
11 dihydroxybenzoic acid (DHB), α -cyano-4-hydroxycinnamic acid (CHCA), sinapinic acid
12 (SA), ferulic acid (FA) and 2,4-hydroxy-phenyl benzoic acid (HPBA). Ferulic acid, sinapinic
13 acid and CHCA have been shown to be effective for the detection of proteins biomarkers
14 (Fenselau & Demirev, 2001, Vaidyanathan, *et al.*, 2002, Williams, *et al.*, 2003) whereas DHB
15 appears to be the best choice for the detection of glycopeptides and glycoproteins (Giebel, *et*
16 *al.*, 2010). The size and the intensities of the peaks of the detected molecules are dependent on
17 the matrix selected for the experiment. DHB and CHCA are usually optimal for the detection
18 of lower mass ions (Hathout, *et al.*, 2000, Williams, *et al.*, 2003, Ruelle, *et al.*, 2004) with a
19 detection up to 10kDa when the proper solvent is used. Both SA and FA have been shown to
20 be better for the detection of higher mass ions (above 15kDa) (Madonna, *et al.*, 2000,
21 Conway, *et al.*, 2001, Ruelle, *et al.*, 2004, Vargha, *et al.*, 2006) but provide a lower sensitivity
22 than CHCA (Wang, *et al.*, 1998, Ruelle, *et al.*, 2004).

23 Intact microorganisms can be directly processed to MALDI-TOF without pre-treatment
24 because most vegetative bacteria are lysed following exposure to water, organic solvent

1
2
3 1 and/or strong acid in the MALDI matrix. When resistant microorganisms such as some viruses,
4
5 2 bacterial spores and yeast cells have to be analysed by MALDI, strong organic acids and/or
6
7 3 alcohols are usually added in pre-treatment steps. Similarly, for some bacterial species (such
8
9 4 as the *Actinomyces*), specific pre-treatment or protein extraction procedures may be useful
10
11 5 (*Bizzini, et al., 2011*).

12
13
14
15
16 6 The marked differences in bioanalytes fingerprints observed with the different matrix
17
18 7 demonstrate that similar standardized preanalytical and analytical procedures than those
19
20 8 performed to establish a database must be followed to ensure accurate identification. This
21
22 9 implies that any modification of the procedure (i) should conform to the manufacturer's
23
24 10 recommendations, (ii) should be analysed to demonstrate that protein profiles remained
25
26 11 consistent with database fingerprints or (iii) should use a new database created with the
27
28 12 modified protocol.

29
30
31
32
33 13 In practice, a microbial sample is mixed with a matrix on a conductive metal plate. The
34
35 14 mixture can be deposited on the metal support or alternatively the microbial sample is
36
37 15 deposited and dried out on the support before the addition of the matrix. After the
38
39 16 crystallisation of the matrix and compound, the target on the metal plate is introduced in the
40
41 17 mass spectrometer where it is bombarded with brief laser pulses from usually a nitrogen laser
42
43 18 (Figure 1). The matrix absorbs energy from the laser leading to the desorption of the analytes
44
45 19 that are then vaporised and ionized in the gas phase. This matrix-assisted desorption and
46
47 20 ionization of the analytes leads to the formation of predominantly singly charged sample ions.
48
49 21 The desorbed and ionized molecules are first accelerated through an electrostatic field and are
50
51 22 then ejected through a metal flight tube that is subjected to a vacuum until they reach a
52
53 23 detector, with smaller ions travelling faster than larger ions. The time of flight required to
54
55 24 reach the detector is dependent on the mass (m) and charge (z) of the bioanalyte and is
56
57 25 proportional to the square root of m/z . Thus, bioanalytes with different m/z that composed a

1 complex sample are separated according to their time of flight (TOF) and create a mass
2 spectrum that is characterized by both the m/z and the intensity of the ions, which is the
3 number of ions of a particular m/z that struck the detector. The results of a spectral signature
4 is composed of spikes ranging usually from 1000 to 20'000 m/z . Usually, MALDI produces
5 single charged ($z=1$) ions and thus the m/z of an analyte corresponds to the value of its mass.

6 **Data analysis**

7 **Biomarkers**

8 Several research groups have demonstrated that biomolecules desorbed from whole
9 unfractionated cells and detected above 4 kDa are intact proteins (Arnold, *et al.*, 1999, Dai, *et*
10 *al.*, 1999, Holland, *et al.*, 1999, Ryzhov & Fenselau, 2001). Most of the biomarkers detected
11 in MALDI-TOF spectra of intact bacterial cells have a molecular mass below 15kDa. A
12 thorough characterization of MALDI biomarkers performed on intact *Escherichia coli* cells
13 have demonstrated that the MALDI detected biomolecules corresponds to proteins from the
14 inside of bacterial cell that are abundant, basic and of medium hydrophobicity (Ryzhov &
15 Fenselau, 2001). Among these MALDI-detected proteins, about half matched ribosomal
16 proteins that are abundant and very basic (Arnold, *et al.*, 1999, Ryzhov & Fenselau, 2001),
17 which is a biochemical trait favourable for efficient ionization during the MALDI process
18 (Krause, *et al.*, 1999). Thus, the abundance (more than 20% of total cell proteins) and the
19 basic nature of ribosomal proteins explain why the majority of the peaks detected in a
20 MALDI-TOF spectrum correspond to ribosomal proteins. In addition, the lysis of bacterial
21 cells in organic solvents and in acidic conditions favouring the extraction of ribosomal
22 proteins combined with the utilisation of a specific matrix allowed the development of a
23 method leading to the ionization of mainly ribosomal proteins (Suh & Limbach, 2004).
24 In a study performed by Ryzhov *et al.* on *E. coli* to characterize the nature of the proteins
25 favoured by MALDI, several additional group of proteins than ribosomal proteins were

1 identified (Ryzhov & Fenselau, 2001). These also included abundant nucleic acid-binding
2 protein, such as *E. coli* DNA-binding protein HU α - and β -subunits (DbhA and DbhB,
3 respectively) and cold-shock proteins, such as cold-shock proteins A, C and E (CspA, CspC,
4 CspE). Similar to ribosomal proteins, these protein families are highly abundant, basic and of
5 medium hydrophobicity. Holland *et al.* potentially identified the acid-resistant precursor
6 proteins HdeA and HdeB observed in the MALDI analysis of both intact *E. coli* and *Shigella*
7 *flexneri* (Holland, *et al.*, 1999). The ion at m/z 7643 in the spectra from *Pseudomonas*
8 *aeruginosa* was mapped to the cold-shock protein CspA and similarly the ion at m/z 7684
9 observed in *P. putida* was identified as the cold-acclimation protein CapB (Fenselau &
10 Demirev, 2001). Sun *et al.* have selected in the MALDI-TOF spectra of *Lactobacillus*
11 *plantarum* 34 reliable biomarkers including 31 ribosomal subunit proteins and 3 ribosome
12 associated proteins identified as a small heat shock protein, a methylase and the DNA-binding
13 protein II (Sun, *et al.*, 2006). A comprehensive study was published by Dieckmann *et al.*
14 where protein identities were assigned to biomarker peaks obtained by whole-cell MALDI-
15 TOF MS of salmonellae (Dieckmann, *et al.*, 2008). Most of the proteins identified in this
16 study were abundant cytosolic proteins that were highly basic including in particular
17 ribosomal proteins, proteins involved in DNA or RNA binding, and other abundant proteins,
18 most of which having a high isoelectric point greater than 9. Thus, examples of biomarker
19 peaks assigned to proteins characterized by a high isoelectric point included not only
20 ribosomal proteins but also many other proteins such as cold shock-like protein CspH,
21 translation initiation factor IF-1 (pI 9.23), DNA binding protein HU α - and β - (pI 9.69 and
22 9.57), the ribosome modulation factor (pI 10.56), and integration host factors A and B (both
23 pI 9.34). Lower pI values proteins detected in this study were in general very abundant
24 proteins including the nucleoid-associated protein H-NS (pI 5.32), the RNA chaperone CspE
25 (pI 8.08), glutaredoxin-1 (pI 5.63) and the phosphocarrier protein HPr (pI 5.6).

1
2
3 1 Thus, most of MALDI-TOF spectra are composed of very conserved proteins with house-
4
5 2 keeping functions affected to a minimal extent by environmental conditions and thus
6
7 3 considered to be optimal for routine identification of bacteria.
8
9

11 4 **Biomarkers Reproducibility**

12
13 5 The reproducibility of MALDI-TOF spectrum of whole bacterial sample is problematic since
14
15 6 large variations can be seen in spectra of the same bacterial species obtained in different
16
17 7 conditions. Many experimental parameters can have an important effect on the observed mass
18
19 8 spectra (Wang, *et al.*, 1998). The reproducibility is dependent on the MALDI-TOF
20
21 9 instrument, the matrix used, the age of the microorganism, the sample:matrix ratio, the sample
22
23 10 concentration, the culture medium and growth conditions (Valentine, *et al.*, 2005). However,
24
25 11 several studies have shown that a subset of peaks from genetically identical bacteria was
26
27 12 conserved in spectra obtained in different experimental conditions (Wang, *et al.*, 1998,
28
29 13 Welham, *et al.*, 1998). These conserved peaks, among which ribosomal proteins are well
30
31 14 represented, explain the feasibility to use MALDI-TOF for bacterial identification even
32
33 15 without the standardization of experimental conditions. These results also suggest that
34
35 16 selected specific conserved biomarker proteins could be used for bacterial identification
36
37 17 irrespective of changes in other biomarkers. However, to optimize the reproducibility, a
38
39 18 standardization of sample preparation (e.g. choice of matrix, concentrations, solvent and
40
41 19 crystallization conditions) has to be established by diagnostic laboratories.
42
43
44
45
46
47
48
49

50 20 **Intra-laboratory reproducibility**

51
52 21 Only a few studies have reported investigations on intra-laboratory reproducibility. In two
53
54 22 studies that were focusing only on the presence or absence of particular peaks but not on peak
55
56 23 intensities, the level of reproducibility obtained was equal to 75% or higher using the same
57
58 24 mass spectrometer and similar sample preparation techniques (Saenz, *et al.*, 1999, Walker, *et*
59
60 25 *al.*, 2002). The reproducibility of MALDI-TOF MS fingerprints was high even when mass

1 spectra were obtained from bacterial cultures propagated in the same standard culture
2 conditions during weeks and even months (Bernardo, *et al.*, 2002).

3 In our laboratory, we observed that the reproducibility is mainly dependent on the quality of
4 the deposit and that the extraction step is not associated with significant supplementary
5 variability. Thus, when considering the higher peaks (≥ 200 intensity units) obtained with *E.*
6 *coli* strain ATCC 25922 in 10 independent analyses, 66 peaks were present in all 10 replicates
7 performed with proteins obtained from the same extraction whereas 78 peaks were present in
8 the 10 spectra obtained from 10 independent extractions (Figure 2A). Similar results were
9 obtained with *S. aureus* strain ATCC 25923 (Figure 2B).

10 **Inter-laboratory reproducibility**

11 The variation of inter-laboratory reproducibility is not surprisingly much higher since small
12 variation in sample preparation and analysis may significantly affect mass fingerprints.
13 Unfortunately, only a few attempts have been made to compare results from different
14 laboratories on the same organism. In addition, inter-laboratory studies based on different
15 comparative settings have been performed and gave very different results. Studies comparing
16 mass spectra of identical microorganisms obtained in different locations but with the same
17 experimental protocols and instruments hardware and software have shown promising results
18 in term of inter-laboratory reproducibility. For instance, two studies using different bacterial
19 species have demonstrated that more than 60% of the peaks observed in mass spectra were
20 similar in separate laboratories (Wang, *et al.*, 1998, Walker, *et al.*, 2002). However, a poor
21 inter-laboratory reproducibility of MALDI-TOF MS of intact microorganisms was
22 demonstrated in a study where three independent laboratories using three different
23 commercial instruments performed a MALDI-TOF MS analysis of identical aliquots of *E. coli*
24 culture prepared and analysed in the same experimental conditions (Wunschel, *et al.*, 2005).
25 In this study, only 25% of the biomarkers were found in common by all three laboratories and

1
2
3 1 more than 50% of the peaks were detected in spectra from only one of the three laboratory. Of
4
5 2 importance, when the mass spectra collected from the instrument of one of the laboratory was
6
7 3 analysed in the other two laboratories, 70% of the mass fingerprints could be identified
8
9 4 correctly as *E. coli*. This finding underlines the importance of the instrument in the
10
11 5 establishment of bacterial fingerprint databases.
12
13
14

15 6 **Application for microorganism identifications**

16
17 7 Two general MALDI-TOF MS methods have been proposed to characterize microorganisms:
18
19 8 (1) mass spectra comparison with fingerprints database and (2) matching of biomarker masses
20
21 9 to a proteome database. In the first approach, generated unique spectra of intact cells are
22
23 10 compared with previously collected fingerprint libraries that are commercially available. This
24
25 11 solution is rapid, simple and is easily adaptable for routine use in diagnostic laboratories. This
26
27 12 approach is convenient to develop specific databases constituted of unique and conserved
28
29 13 peaks that can be used for species and subspecies identification, independently of the culture
30
31 14 conditions used to grow the microorganism (Carbonnelle, *et al.*, 2007). In the second
32
33 15 approach, the biomarker masses associated with an unknown microorganism are identified by
34
35 16 matching protein molecular masses in the spectrum with protein molecular masses predicted
36
37 17 from sequenced genomes (Demirev, *et al.*, 1999). This method is based on the observation
38
39 18 that the majority of observed biomolecules above 4000 m/z in MALDI-TOF spectra of whole
40
41 19 cell extracts are proteins. An available algorithm predicts protein masses *in silico* from the
42
43 20 genomes and seeks matches with experimentally derived masses (Pineda, *et al.*, 2000).
44
45 21 However, this application is limited to microorganisms whose genomes are sequenced and
46
47 22 further development in strategies for organization of the proteome database is required. The
48
49 23 advantage of such a bioinformatics-based approach compared to bacterial fingerprinting is
50
51 24 that the identification tolerates variations in the protein profiles and thus differences in culture
52
53 25 growth and sample treatment conditions.
54
55
56
57
58
59
60

1 **Bacterial identification**

2 The identification of microorganisms in clinical diagnostic microbiology laboratories is
3 nowadays mainly performed by analysis of biochemical reactions and phenotypic
4 characteristics, such as growth on different media, colony morphology and Gram staining.
5 When combined, these routine laboratory techniques ensure an accurate identification of most
6 microorganisms but are costly, require time and need in some cases well-trained technician
7 for correct interpretation. One of the major advantages of using MALDI-TOF technology for
8 bacterial identification is the time-to-result, which is reduced from 24-48h to less than an
9 hour. In addition, MALDI-TOF allowed accurate bacterial identification of a large variety of
10 bacteria, that only exhibit few phenotypic traits and that were identified by 16S rRNA gene
11 sequencing prior to the MALDI-TOF era (Bizzini, *et al.*, 2011).

12 **Routine identification**

13 Several approaches are commonly used in routine diagnostic laboratories. One typical
14 approach is to pick bacterial isolates colonies freshly grown on defined agar medium with a
15 sterile tip and to smear a thin film onto a ground steel MALDI target plate. The microbial film
16 is then overlaid with a MALDI matrix selected as recommended by the MALDI-TOF
17 manufacturers, typically 1.5 µl CHCA in 50% acetonitrile/2.5% trifluoroacetic acid for the
18 Bruker instrument and 0.5 µl of 20mg DHB dissolved in 1ml water-ethanol-acetonitrile
19 [1:1:1] mix for the Shimadzu instrument. In our laboratory, to increase identification yield, we
20 routinely add formic acid on smeared micro-organisms before adding the matrix. The sample-
21 matrix mixture is dried at room temperature and then introduced in the MALDI-TOF
22 instrument for data acquisition. The data are processed by the associated softwares (see
23 above) and the spectra are compared to reference libraries for bacterial identification. A
24 protein extraction step using ethanol-acetonitrile is performed when direct application
25 procedure failed.

1
2
3 1 Several studies have analysed the bacterial identification efficiency of these two instruments
4
5 2 (Bruker and Shimadzu) with their respective software and databases (Table 1). We will
6
7
8 3 present here the results of (1) two intra-laboratory studies using the Bruker system (Seng, *et*
9
10 4 *al.*, 2009, van Veen, *et al.*, 2010), (2) an intra-laboratory study evaluating the two instruments
11
12 5 using the same microbial samples (Cherkaoui, *et al.*, 2010), and (3) a large international
13
14 6 interlaboratory study performed with the Bruker instrument (Mellmann, *et al.*, 2009).

17
18 7 Using the Bruker system, 327 clinical isolates previously identified by conventional
19
20 8 techniques were analysed by MALDI-TOF MS by Van Veen *et al.* The authors observed a
21
22 9 95.1% correct identification at the genus level and a 85.6% at the species level (van Veen, *et*
23
24 10 *al.*, 2010). The same group performed a prospective validation study on 980 clinical isolates
25
26 11 of bacteria and yeast that showed a 92.2% correct identification by MALDI-TOF, a
27
28 12 performance significantly better than the 83.1% identification obtained with conventional
29
30 13 biochemical systems. Correct species identification by MADLI-TOF MS was observed in
31
32 14 97.7% of *Enterobacteriaceae*, 92% of nonfermentative Gram-negative bacteria, 94.3% of
33
34 15 staphylococci, 84.8% of streptococci, 84% of bacteria of the HACCEK group (*Haemophilus*,
35
36 16 *Actinobacillus*, *Cardiobacterium*, *Capnocytophaga*, *Eikenella* and *Kingella*) and 85.2% of
37
38 17 yeasts. In this work, misidentification was clearly associated with insufficient spectra from
39
40 18 suitable reference strains in the reference spectra database.

41
42
43
44
45
46
47
48 19 Seng *et al.* have conducted a prospective routine MALDI-TOF MS identification analysis
49
50 20 with the Bruker system on 1660 bacterial isolates in parallel with conventional phenotypic
51
52 21 bacterial identification (Seng, *et al.*, 2009). Discrepancies were resolved by 16S rRNA and
53
54 22 *rpoB* gene sequencing. They have shown that 95.4% of the isolates were correctly identified
55
56 23 by MALDI-TOF MS among which 84.1% at the species level and 11.3% at the genus level
57
58 24 only. Absence of identification (2.8% of isolates) and incorrect identification (1.7% of
59
60 25 isolates) were mainly due to improper database entries. They have estimated that the MALDI-

1
2
3 1 TOF identification required an average time of 6 minutes for an estimated 70-80 % reduced
4
5
6 2 cost compared to conventional methods of identification.
7

8
9 3 Cherkaoui *et al.* have evaluated the two main MALDI-TOF MS systems, Bruker and
10
11 4 Shimadzu, in a comparative study with 720 bacterial isolates under routine clinical laboratory
12
13 5 conditions (Cherkaoui, *et al.*, 2010). The isolates were analysed in parallel on both devices
14
15 6 according to the manufacturers' default recommendations. The MALDI-TOF MS results were
16
17 7 compared with conventional biochemical identification tests and discordant results were
18
19 8 resolved with 16S rRNA gene sequencing. The Bruker MS system gave high-confidence
20
21 9 identification for 680 of 720 isolates (94.4%) whereas the Shimadzu MS showed a high-
22
23 10 confidence identification for 639 isolates (88.8%). These results showed also that only 6/680
24
25 11 (0.9%) of the Bruker and 3/639 (0.5%) of the Shimadzu identifications gave an incorrect
26
27 12 high-confidence identification at the species level. All the high-confidence MS identifications
28
29 13 were accurate at the genus level. In addition, the Bruker MS system has identified 9 (69%)
30
31 14 and the Shimadzu system 5 (38%) of 13 isolates that were not identified by conventional
32
33 15 phenotyping methods.
34
35
36
37
38
39

40 16 Interlaboratory species identification was assessed in a large international multicenter study
41
42 17 (Mellmann, *et al.*, 2009) using the Bruker system. In this study, eight participating
43
44 18 laboratories received 60 blind-coded samples for MALDI-TOF MS species identification and
45
46 19 98.75% were correctly identified at the species level. Six of the eight laboratories identified
47
48 20 all 60 samples correctly. Out of a total of 480 samples, 6 samples were misidentified and one
49
50 21 sample did not give any valid result due to low signal intensity. Thus, in contrast to other
51
52 22 studies (Wang, *et al.*, 1998), the utilization of a commercial system developed for routine use
53
54 23 provided high reliability for bacterial identification.
55
56
57
58
59
60

1
2
3 1 Even though excellent results have been shown for bacterial identification by MALDI-TOF
4
5 2 MS, both the diagnostic yield (identification at the genus, species or strain level) and the
6
7 3 accuracy of identification depends on the taxonomy and in the quality of the databases. As
8
9 4 shown by many studies, most of the bacterial groups including *Enterobacteriaceae*,
10
11 5 nonfermentative Gram-negative bacteria, staphylococci and haemolytic streptococci were
12
13 6 correctly identified as the species level (Seng, *et al.*, 2009, Cherkaoui, *et al.*, 2010, van Veen,
14
15 7 *et al.*, 2010). Regarding staphylococci, the MALDI-TOF MS has brought up an important
16
17 8 advantage by allowing rapid and simplified identification of both *S. aureus* and of some
18
19 9 species belonging to coagulase-negative staphylococci (CoNS). Unlike most commercial
20
21 10 identification systems that allow a rapid identification of only *S. aureus*, the MALDI-TOF MS
22
23 11 allows a correct identification of various CoNS species (Speers, *et al.*, 1998, Bernardo, *et al.*,
24
25 12 2002, Dupont, *et al.*, 2010). In a comparative study between MALDI-TOF MS and two rapid
26
27 13 identification automated systems, BD Phoenix (BD Diagnostic Systems, France) and Vitek-2
28
29 14 (bioMérieux, France), the identification of 234 CoNS belonging to 20 different species
30
31 15 showed that the MALDI-TOF performance was significantly better (93.2%) than Phoenix
32
33 16 (75.6%) and Vitek-2 (75.2%) (Dupont, *et al.*, 2010). Overall, MALDI-TOF appears to be
34
35 17 excellent at identifying various staphylococci species as demonstrated by the congruence of
36
37 18 99.3% (444/447) between MALDI-TOF and *rpoB* sequence-based identifications (Spanu, *et*
38
39 19 *al.*, 2011). Since CoNS can cause serious infections and are frequently associated with
40
41 20 hospital-acquired infections, the rapid identification at the species level by MALDI-TOF is
42
43 21 very useful in distinguishing clinically significant CoNS from contaminant strains (von Eiff,
44
45 22 *et al.*, 2002).

23 **Problematic identifications**

24 Most of the problematic identifications encountered in most of the recent studies concerned
25 the viridans streptococci group, the pneumococci and anaerobic bacteria (Table 2). Viridans

1
2
3 1 streptococci and pneumococci were commonly misidentified mainly due to an incomplete
4 database reference library. In the study by Seng *et al.*, nearly 50% of *S. pneumoniae* isolates
5 were misidentified as *Streptococcus parasanguinis* (a close related species within the mitis
6 group of *Streptococcus* species (Kawamura, *et al.*, 1995)) because the database contained only
7 three *S. pneumoniae* and two *S. parasanguinis* reference spectra (Seng, *et al.*, 2009). The
8 problem was solved by adding additional *S. pneumoniae* isolates reference spectra to the
9 database which clearly indicates that the database need to be updated with multiple spectra of
10 well-characterized streptococcal species. Until now, the identification of *Streptococcus* spp.
11 remains a problem for MALDI-TOF MS identification especially for closely related species
12 such as *S. pneumoniae*, *S. mitis* and *S. parasanguinis*. In the case of pneumococci, the use of
13 MALDI-TOF MS for identification is further impaired by the weak extraction yield caused by
14 the presence of a capsule. Thus, identification of *S. pneumoniae* should not solely rely on
15 MALDI-TOF since false identification can results in important clinical outcomes. In the study
16 of Cherkaoui *et al.*, the diagnostic yield for streptococcal species and for Gram-negative
17 anaerobes was less than 50% with an accuracy of high-confidence species identification of
18 only 57.1% for streptococci with the Bruker system and of 71.4% with the Shimadzu MS
19 system (Cherkaoui, *et al.*, 2010).

20
21 To date, only a few studies have analysed the usefulness of MALDI-TOF for routine
22 identification of anaerobic bacteria. Seng *et al.* showed that an improved database is required
23 since 50% of the total isolates (46) showing no identification by MALDI-TOF MS were
24 anaerobic bacteria including *Fusobacterium nucleatum* and non-*Clostridium* anaerobes that
25 had no reference in the Bruker database (Seng, *et al.*, 2009). In contrary, for anaerobic
species (e.g several *Bacteroides* species) with sufficient spectra in the database, the
identification by MALDI-TOF MS was better compared to conventional biochemical
methods. These fastidious organisms are poorly identified using phenotypic methods with a

1 lack of specificity and ambiguous or false identification. There is thus an important need to
2 improve the database entries with additional anaerobes isolates (Bessedé, *et al.*, 2011).

3 Similar to other studies, Blondiaux *et al.* have demonstrated the difficulties to identify
4 viridans streptococci, pneumococci as well as HACCEK bacteria but also *Shigella* and several
5 strictly aerobic bacteria (*Aeromonas* spp., *Achromobacter* spp., *Alcaligenes* spp.) (Blondiaux,
6 *et al.*, 2010). In this study, the mass spectra of six *Shigella* isolates were similar to several *E.*
7 *coli* strains present in the Biotyper database. In another study, the misidentification of all
8 *Shigella sonnei* isolates with *E. coli* was also documented (Seng, *et al.*, 2009).

9 Using 43 selected *Mycobacteria* strains, a mycobacterial database could be engineered
10 comprising species-specific spectral profiles allowing identification of 44 species at the
11 species level and of 9 strains of the *M. abscessus* complex and the *M. tuberculosis* complex at
12 the mycobacterial clade level (Lotz, *et al.*, 2010). Under the preanalytical and analytical
13 conditions used in this study, subspecies of the *M. abscessus* complex (*M. abscessus*, *M.*
14 *massiliense* and *M. bolletti*) and the *M. tuberculosis* complex (*M. tuberculosis*, *M. bovis*, *M.*
15 *microti* and *M. africanum*) produced indistinguishable mass profiles due to their high degree
16 of genetic similarity. Using this microbial database, 311 strains grown on solid medium were
17 analysed by MALDI-TOF MS allowing a 97% correct identification, 67% at the species level
18 and 30% at the complex level respectively. No misidentification was observed. When bacteria
19 were grown on liquid media, correct identification was reduced to 77%, likely due to a
20 reduced number of bacterial load or to potential interference with components of the liquid
21 media. Interestingly, the authors observed that an increase in number of replicates (up to 5)
22 did correlate with an increase probability of good identification, especially for slow-growing
23 mycobacteria. Overall, several studies demonstrate that MALDI-TOF MS provides high
24 reproducibility and specificity for mycobacterial identification and represents an alternative to

1
2
3 1 other time consuming and fastidious conventional mycobacterial identification methods
4
5 2 (Hettick, *et al.*, 2004, Lefmann, *et al.*, 2004, Pignone, *et al.*, 2006, Lotz, *et al.*, 2010).
6
7

8
9 3 In our study analysing the performance of MALDI-TOF MS for the identification of 1371
10
11 4 bacterial isolates routinely isolated in clinical microbiology laboratories and characterized by
12
13 5 conventional methods, 1278 (93.2%) bacterial isolates were identified at the species level, 73
14
15 6 (5.3%) were only identified at the genus level and 20 (1.5%) gave no reliable identification
16
17 7 (Bizzini, *et al.*, 2010). Among the 1278 isolates identified at the species level, 63 (4.9%) were
18
19 8 misidentified. The majority of discordant results (42/63) were explained by discordances due
20
21 9 to the MALDI-TOF database, 14 were due to poor discrimination of the spectra of closely
22
23 10 related species such as *Shigella* spp. and *E.coli*, and 7 were caused by errors in the initial
24
25 11 conventional phenotypic and biochemical identifications.
26
27

28
29
30
31 12 Many of the bacterial identification that can be done only at the genus level are due to
32
33 13 incomplete reference spectra covering many different isolates or species from a given genus.
34
35 14 For instance, only 1 reference spectrum of *P. acnes* (strain DSM 1897) or *Bacillus cereus* are
36
37 15 included in the Bruker database which is totally insufficient to cover the true diversity of these
38
39 16 bacteria and thus to identify accurately these microorganisms (Bizzini, *et al.*, 2010) . In
40
41 17 addition, mislabelling of bacterial species in the database can cause misidentification by
42
43 18 MALDI-TOF MS. In the study by Seng *et al.*, 7 *S. maltophilia* isolates were incorrectly
44
45 19 identified as *P. hibiscicola* which is an invalid name for a nonfermenting Gram-negative rod
46
47 20 that was demonstrated to be *S. maltophilia* (Seng, *et al.*, 2009).
48
49

50
51
52
53 21 These studies show that a complete and representative database is an essential requirement for
54
55 22 accurate identification of isolates by MALDI-TOF MS. A frequent update of the reference
56
57 23 library database with spectra of appropriate poorly represented reference strains by the
58
59
60

1 manufacturers but also by routine diagnostic laboratories can significantly impact the
2 MALDI-TOF identification performance.

3 **Impact of Sample preparation on MS identification**

4 Sample preparation has not been shown to be a major issue for problematic identifications.
5 Samples and matrix prepared according to manufacturer's instructions usually guarantee high
6 quality spectral fingerprints required for efficient MALDI-TOF identifications. In most cases,
7 the composition of an appropriate matrix containing strong solvent ensures efficient bacterial
8 lysis required for MALDI-TOF analysis. When invalid results are initially obtained by
9 MALDI-TOF MS following analysis of intact bacteria directly deposited on MALDI target
10 plate, a step of bacterial protein extraction with acid-containing sample solvents improving
11 cell lysis solve the problem in most cases. Bizzini *et al.* have shown that a formic acid-
12 acetonitrile extraction step was required to get a valid MALDI-TOF MS identification for
13 25.6 % of the 1278 valid isolates (Bizzini, *et al.*, 2010). The yield of valid score from direct
14 application was almost the same, about 75%, for both Gram-positive and Gram-negative
15 bacteria. For instance, the yields of valid scores without extraction step were equal to 79% for
16 *S. aureus*, 82% for *Enterococcus faecalis*, 92% for *Pseudomonas aeruginosa*, 74% for *E. coli*,
17 58% for *Klebsiella pneumoniae* and 58% for *Staphylococcus epidermidis*. However, the
18 authors concluded that protein extraction prior to MALDI-TOF analysis should be performed
19 only in particular cases known to be problematic such as colonies isolated from urine culture
20 devices and/or MacConkey agar which contains crystal violet, a possible interfering substance
21 affecting mass peak signals. Indeed, the higher identification rate obtained after an extraction
22 step largely compensates the longer hand-on-time associated with an extraction procedure.
23 This was also demonstrated by a study performed by Liu *et al.* that have developed a
24 universal sample preparation for characterization of bacteria by MALDI-TOF MS (Liu, *et al.*,
25 2007). The protocol, consisting of a pretreatment of bacteria with acidic sample solvents and

1
2
3 1 mixing with CHCA or CMBT matrix, could be used to analyse both Gram-positive bacteria,
4
5 2 including spore-producing *B. anthracis* and non-spore-producing *S. aureus*, and Gram-
6
7 3 negative bacteria such as *Y. pestis*, *E. coli*, and *B. cepacia* that are characterized by high
8
9 4 extracellular-polysaccharide contents.
10
11

12
13
14 5 However, for some microorganisms, insufficient cell lysis and/or low quantity of sample
15
16 6 material can be problematic for efficient MALDI-TOF identification and require the use of
17
18 7 alternative identification approaches such as 16S rRNA gene sequencing. A study by Bizzini
19
20 8 *et al.* focusing on the identification of 410 clinical isolates that could not be identified with
21
22 9 conventional laboratory methods showed that 133/410 (32.4%) isolates could not be either
23
24 10 reliably identified with MALDI-TOF (Bizzini, *et al.*, 2011). The failure to obtain a reliable
25
26 11 identification was due to the absence of reference spectra in the BioTyper database for 58%
27
28 12 (78/133) of the isolates and to poor protein spectral signals for 41.4% (55/133) of the isolates.
29
30 13 The authors supposed that the poor spectrum quality observed could be due to either the
31
32 14 difficulty to lyse the cell wall of some bacteria such as Gram-positive bacilli and/or to
33
34 15 fastidious growth of some isolate, which yielded only small amount of available sample
35
36 16 material. Difficult to identify microorganisms belonging to the genus *Actinomyces*, *Gemella*,
37
38 17 *Nocardia* and *Streptomyces* could be observed in this study.
39
40
41
42
43
44

45 18 The rate of successful identification is directly linked to the amount of microorganism
46
47 19 available. We have observed that the rate of correct identification is especially poor when the
48
49 20 subculture has been incubated on a plate for less than 4 hours (Figure 3). Thus, when we tried
50
51 21 to identify various bacterial species isolated from positive blood cultures and sub-cultured on
52
53 22 agar, we observed that only 30% of bacteria could be successfully identified after 2 hours of
54
55 23 incubation (Figure 3C). This identification rate was significantly lower for Gram-positive
56
57 24 cocci, remaining below 60% after 6 hours. This is likely due to the amount of bacteria
58
59 25 available after short incubation period (Figure 3B). Indeed, using ten-fold dilutions of *E. coli*
60

1 strain ATCC 25922 and *S. aureus* strain ATCC 25923, we could show that as much as 10^6
2 bacteria/well were necessary to consistently obtain a spectrum (Figure 3A) ensuring a score
3 above 2 and that when the amount of bacteria was ranging between 10^2 to 10^4 bacteria/well,
4 the score was always below 1.7 (data not shown). Lower amount of bacteria may however be
5 identified with a different identification algorithm. Hsieh *et al.* have demonstrated that as few
6 as 5×10^3 cells from a pure strain can be identified by MALDI-TOF MS using particular
7 analysis approaches based on selected markers (Hierarchical Clustering Analysis and direct
8 classification model construction) (Hsieh, *et al.*, 2008). Interestingly, using the classification
9 model analysis, the authors showed that successful MALDI-TOF MS identification can also
10 be achieved from a bacterial species mixture consisted of as less as 3×10^4 cells. This study
11 opens new perspectives for the direct identification of low abundant bacteria located in mixed
12 flora without the pre-requirement of bacterial isolation and culturing.

13 **Fungal identification**

14 Fungal identification still largely relies on phenotypic traits. However, a few days are
15 necessary to obtain mature fungi with phyalids (phyalids are conidiogenous cells observed in
16 a type of fungal asexual reproduction leading to the production of conidia). This time delay
17 may be important given the morbidity and mortality of fungal infections, especially common
18 and life threatening among neutropenic patients. Thus, like PCR and sequencing, MALDI-
19 TOF has the potential to provide accurate and objective identification at species level, with
20 the additional advantage of rapidity and reduced costs compared to PCR and sequencing.

21 MALDI-TOF MS systems for the identification of microorganisms was successfully adapted
22 for the identification of fungi in the past 10 years. In 2000, Welham *et al.* were among the
23 first to perform fungal identification using the MALDI-TOF MS approach (Welham, *et al.*,
24 2000). Three fungal species, *Penicillium* spp., *Scytalidium dimidiatum* and *Trychophyton*

1
2
3 1 *rubrum*, showed distinct spectral fingerprints allowing accurate species distinction. Since
4
5 2 then, many studies have demonstrated the usefulness of the MALDI-TOF application for the
6
7 3 identification of various fungal groups such as penicillia, aspergilla, *Fusarium*, *Trichoderma*
8
9 4 and dermatophytes. However, until now, MALDI-TOF MS is mainly used for the routine
10
11 5 identification of yeasts whereas further development has to be accomplished in database
12
13 6 libraries and sample preparation protocols in order to implement this identification approach
14
15 7 to other group of fungi such as filamentous fungi and dermatophytes.
16
17
18
19

20 8 **Yeasts**

21
22
23 9 The databases of the associated softwares (Biotyper and SARAMIS) of the two main
24
25 10 MALDI-TOF instruments contains reference spectra of multiple clinical yeast isolates,
26
27 11 including several *Candida* spp. and *Cryptococcus neoformans*, which allows the use of
28
29 12 MALDI-TOF in routine yeast laboratory identification (Table 1).
30
31
32

33 13 Marklein *et al.* evaluated MALDI-TOF MS for the rapid routine identification of clinical
34
35 14 yeast isolates and showed that 92.5 % (247/267) of clinical isolates of *Candida*,
36
37 15 *Cryptococcus*, *Saccharomyces*, *Trichosporon*, *Geotrichum*, *Pichia*, and *Blastoschizomyces*
38
39 16 spp. were accurately identified (Marklein, *et al.*, 2009). In a study performed by Van Veen *et*
40
41 17 *al.*, 85% of 61 yeast isolates comprising 12 different species were correctly identified without
42
43 18 occurrence of major errors (van Veen, *et al.*, 2010). Bizzini *et al.* achieved a 100% correct
44
45 19 identification of 24 yeast isolates belonging to 12 different species (Bizzini, *et al.*, 2010). The
46
47 20 suitability of the two commercially available MALDI-TOF MS systems, Bruker and
48
49 21 Shimadzu, and their respective associated softwares and databases, Biotyper and Saramis, was
50
51 22 tested for rapid species identification of yeasts in a clinical diagnostic approach (Bader, *et al.*,
52
53 23 2010). Both MALDI-TOF MS systems have showed a similar species identification rate of
54
55 24 97.6 % for Bruker/Biotyper and 96.1 % for Shimadzu/Saramis that were comparable to the
56
57 25 biochemical tests rate (96.9%). Based on isolates that were contained in the respective
58
59
60

1 database, no misclassifications were seen with Saramis and fewer misidentifications were
2 reported by the Biotyper compared to classical approaches. Using the Bruker MALDI-TOF
3 system, Stevenson *et al.* have created a spectral database library for 109 reference strains of
4 yeast representing 44 species and 8 genera to evaluate the use of MALDI-TOF MS for the
5 rapid identification of yeast species (Stevenson, *et al.*, 2010). This library was challenged with
6 197 clinical isolates. Three isolates gave no spectral score since no reference spectrum were
7 included in the database library. Of the remaining 194 clinical isolates, 192 (99.0%) were
8 correctly identified at the species level and two organisms gave consistently low spectral
9 scores that could not be identified. In summary, the use of MALDI-TOF mass spectrometry
10 for the identification of clinically relevant yeasts is rapid and accurate providing that the
11 database is constructed with a comprehensive collection of accurately identified reference
12 strains.

13 **Filamentous fungi**

14 Chen *et al.* successfully identified several *Penicillium* species directly from intact fungal
15 spores mixed with the MALDI matrix (Chen & Chen, 2005). Hettick *et al.* have achieved
16 100% correct identifications of 12 *Penicillium* species by bead beating fungal samples
17 resuspended in a acetonitrile/trifluoroacetic acid solvent prior to MALDI-TOF analysis
18 (Hettick, *et al.*, 2008). The observed mass spectra contained abundant peaks in the range
19 5000-20000 m/z allowing unambiguous discrimination between species. In addition, a
20 biomarker common to all *Penicillium* mass fingerprints was observed at m/z of 13.9 kDa.

21 Using an extraction method similar to that used for *Penicillium* species, Hettick *et al.* obtained
22 also highly reproducible mass spectral fingerprints for 12 species of *Aspergillus* and 5 strains
23 of *A. flavus* (Hettick, *et al.*, 2008). The 12 species were correctly identified but only a 95%
24 accurate identification was obtained at the strain level. It was also pointed out that *Aspergillus*
25 *niger* could not be distinguished from *Aspergillus chevalieri*. The authors concluded that the

1
2
3 1 identification of *Aspergillus* spp. with MALDI-TOF MS would require a comprehensive
4
5 2 database of at least 180 species of *Aspergillus*. A study showed that different species of
6
7 3 *Aspergillus*, including aflatoxigenic and non-aflatoxigenic spp., could be characterized
8
9 4 directly from intact spores (Li, *et al.*, 2000). However, the authors reported certain
10
11 5 discrepancies due to the difficulties encountered to discriminate the spectra obtained with
12
13 6 some of the analysed species. A database including the reference spectra of 28 clinically
14
15 7 relevant *Aspergillus* species was engineered in a recent study by including species-specific
16
17 8 fingerprints of both young and mature colonies of reference strains (Alanio, *et al.*, 2010). The
18
19 9 performance of the database was tested on 124 clinical and 16 environmental *Aspergillus*
20
21 10 isolates resulting in a 98.6% (138/140) correct identification with 100% specificity (0%
22
23 11 misidentification). This study has demonstrated that a complete fingerprint database including
24
25 12 spectra from both young and mature fungal colonies makes MALDI-TOF a robust method for
26
27 13 *Aspergillus* species identification regardless of the maturity of the tested isolates.
28
29
30
31
32
33

34 14 The identification of multiple *Fusarium* spp. has also been demonstrated by various studies.
35
36 15 In the study by Marinach-Patrice *et al.*, 62 strains or isolates belonging to 9 *Fusarium* spp.
37
38 16 were subjected to both molecular identification and MALDI-TOF MS analysis (Marinach-
39
40 17 Patrice, *et al.*, 2009). Following updating of the BioTyper database with 13 strains of 5
41
42 18 *Fusarium* spp., 57 (92%) strains were correctly identified by MALDI-TOF MS analysis. Only
43
44 19 one *Fusarium pseudonygamai* isolate was misidentified and four *Fusarium* isolates were not
45
46 20 identified due to absence of reference spectra in the database. MALDI-TOF MS was also used
47
48 21 successfully to identify 5 mycotoxin-producing *Fusarium* spp. by direct analysis of spores
49
50 22 which yielded highly reproducible MS profiles (Kemptner, *et al.*, 2009).
51
52
53
54
55

56 23 **Dermatophytes**

57 24 The most important clinical fungal dermatophytes species, *T. rubrum*, *Trychophyton*
58
59 25 *interdigitale*, *Trychophyton tonsurans* and *Arthroderma benhamiae*, originating from skin and
60

1
2
3 1 nail were recently identified using the SARAMIS database (Erhard, *et al.*, 2008). Except for
4
5 2 one *T. rubrum* strain, a high level of confidence (99.9%) was obtained in this study where
6
7 3 sufficient MS spectra were used to produce a super-spectrum for each species.
8
9

10 11 4 **Problematic identifications**

12
13 5 Similar to bacteria, absence of identification or misidentification of fungal species by
14
15 6 MALDI-TOF MS analysis are essentially due to absence, mistakes or incomplete reference
16
17 7 spectra in the database (Table 2). High quality MS spectra are usually easily obtained with
18
19 8 both fungal hyphae and spores following manufacturer's instruction or based on the
20
21 9 recommendation of reference studies. For instance, because of their cell wall structure, yeasts
22
23 10 need an extraction step to yield a valid score of identification by MALDI-TOF MS. In the
24
25 11 study of Bizzini *et al.*, only 4% (1/24) of the valid results were obtained by direct application
26
27 12 of the colony on the MALDI plate (Bizzini, *et al.*, 2010) and an extraction method prior to
28
29 13 analysis by MALDI-TOF was also shown to be mandatory to obtain appropriate spectra in the
30
31 14 study performed by van Veen *et al.* (van Veen, *et al.*, 2010). The spectra of several
32
33 15 *Penicillium* spp. obtained from bead beating fungal samples resuspended in an acidic solvent
34
35 16 prior to MALDI-TOF analysis was more discriminative (abundant peaks in the range 5000-
36
37 17 20000 m/z) than spectra obtained directly from intact spores (range of 2600-7378 m/z) (Chen
38
39 18 & Chen, 2005, Hettick, *et al.*, 2008). However, Valentine *et al.* identified *Aspergillus niger*,
40
41 19 *Rhizopus oryzae*, *Trichoderma reesei* and *Phanerochaete chrysosporium* using either intact
42
43 20 spores, hyphae or extracts showing that intact cells, sonicated cells and acid-treated cells
44
45 21 yielded similar spectra (Valentine, *et al.*, 2002).
46
47
48
49
50
51
52
53

54 22 The main problem is that, unfortunately, very few reference spectra are currently included in
55
56 23 the database of commercially available MALDI-TOF MS systems. Most of the studies
57
58 24 showing that the MALDI-TOF MS identification is a powerful system for the characterization
59
60 25 and identification of fungi have built and used their own reference spectra database and have

1
2
3 1 developed their own sample preparation techniques. There is thus still a lack of standardized
4
5 2 extraction protocols regarding filamentous fungi.
6
7

8
9 3 In addition, the spectral signal of filamentous fungi may be strongly influenced by the
10
11 4 phenotype of the fungus including basidiospore, monokaryon, dikaryon, fruiting body, surface
12
13 5 mycelium, strands and substrate mycelium. Moreover, vegetative mycelium grown on agar
14
15 6 shows multiple zones that correspond to different ages or developmental stages. These
16
17 7 variations may thus influence the spectral reproducibility of the same isolate and a
18
19 8 comprehensive database of filamentous fungi should include MS fingerprints of several
20
21 9 different developmental forms to guarantee high yields and accuracy of identification as
22
23 10 demonstrated by Alanio *et al.* (Alanio, *et al.*, 2010).
24
25
26
27

28 29 11 **Direct identification from samples**

30
31
32 12 Given the accuracy of MALDI-TOF for bacterial identification, this technology might be
33
34 13 directly applied to some clinical samples, such as blood, urines, cerebrospinal fluid, pleural
35
36 14 fluid, peritoneal liquid and synovial fluid. The major limitation is the amount of bacteria
37
38 15 present in the samples and the limit of detection of current MALDI-TOF protocols. To
39
40 16 circumvent this difficulty, large volumes are used for blood and urines and an additional
41
42 17 enrichment by culture is available for blood (see paragraphs below). Regarding cerebrospinal
43
44 18 fluid, Nyvang Hartmeyer *et al.* successfully identified *S. pneumoniae* 30 minutes after
45
46 19 receiving a sample supporting the proof-of-concept (Nyvang Hartmeyer, *et al.*, 2010).
47
48 20 However, practically, bacterial identification from cerebrospinal fluid, strongly limited by the
49
50 21 low bacterial load and the limited volume available, is yet not applicable in routine diagnostic
51
52 22 laboratories.
53
54
55
56
57

58 59 23 **Blood (hemoculture)**

60

1
2
3 1 Bloodstream infection, septic shock and endocarditis represent severe diseases with important
4
5 2 mortality and morbidity. Blood culture represents the best way to establish the etiology of
6
7 3 such infections and to guide antimicrobial treatment. This is important since rapid and
8
9 4 appropriate antimicrobial therapy is pivotal to reduce poor outcome (Kollef, 2000). Indeed,
10
11 5 the fatality rate was 20% for bloodstream infection patients treated with appropriate therapy,
12
13 6 and 34% for patients treated with inappropriate therapy (Leibovici, *et al.*, 1998). The rapid
14
15 7 notification of the Gram stain result from positive blood culture has also a positive impact for
16
17 8 adaptation of antimicrobial regimen (Munson, *et al.*, 2003). Consequently, the precise
18
19 9 identification of a microorganism isolated from positive blood culture early after Gram stain
20
21 10 notification will likely help clinician to better adapt the antimicrobial therapy. As an example,
22
23 11 the impact on the choice of the antibiotic will likely be significant when Gram-positive cocci
24
25 12 are identified from blood cultures, since the antibiotic susceptibility of *E. faecium* is clearly
26
27 13 different from that of alpha-hemolytic streptococci.

28
29
30
31
32
33
34 14 Quantitative blood-cultures have demonstrated that bacterial load during bloodstream
35
36 15 infection is very low in adults, often less than 1-10 colony forming unit/ml. In practice, blood
37
38 16 samples are inoculated into bottles containing broth media and incubated in automated
39
40 17 instruments monitoring CO₂ concentrations released during bacterial growth. At the
41
42 18 automated growth detection time, the bacterial load may reach a heavy growth up to 10⁶ to
43
44 19 10⁸ colony forming units/ml. In our laboratory, *Enterobacteriaceae*, *Pseudomonas aeruginosa*
45
46 20 and aerobic Gram-positive cocci were generally detected when present at 10⁷ bacteria/ml.
47
48 21 Such bacterial concentration might be adequate to allow accurate bacterial identification using
49
50 22 mass spectrometry.

51
52
53
54
55
56 23 However, the blood culture bottle fluid represent a complex solution with multiple non-
57
58 24 bacterial proteins isolated from patient's blood and nutrient growth media. These proteins
59
60 25 alter the specific bacterial mass spectrometry profile obtained by MALDI-TOF and have a

1
2
3 1 detrimental effect on the performance of algorithm used to query the database containing
4
5 2 bacterial mass spectrometry profiles.
6
7

8
9 3 The preparation of a bacterial pellet from positive blood culture includes a differential
10
11 4 centrifugation step to discard blood cells, an erythrocyte lysis step and a subsequent washing
12
13 5 step to remove additional non-bacterial components. Application of this protocol allows the
14
15 6 identification in less than 1 hour as compared to overnight growth of bacteria required to
16
17 7 obtain pure colonies for biochemical identification.
18

19
20
21 8 Recent studies (Table 3) have shown that a correct identification by MALDI-TOF is obtained
22
23 9 in >80% of cases starting from blood culture bottles. The results varied according to the
24
25 10 bacterial pellet preparation protocol and the type of microorganism present in blood cultures.
26
27 11 Using ammonium chloride as lysing agent, 89% of Gram-negative bacteria and 73% of Gram-
28
29 12 positive bacteria (i.e. 90% for *Staphylococci* and 33% for *Streptococci*) were correctly
30
31 13 identified at the species level (Prod'hom, *et al.*, 2010). No identification was observed in 21%
32
33 14 of cases. The lower performance of MALDI-TOF for Gram-positive bacteria and particularly
34
35 15 *Streptococci* has also been observed in other studies (Table 3). Similar to MALDI-TOF
36
37 16 identifications from pure microbial isolates, several hypothesis have been suggested to
38
39 17 explain discordant results obtained from blood cultures: i) the close relatedness of the
40
41 18 different species especially within *Streptococci*, notably within *Streptococcus mitis* group
42
43 19 (i.e., *S. pneumoniae*, *S. mitis*, *S. sanguinis*, *S. oralis*) conferring closely related MALDI-TOF
44
45 20 spectrum profiles, ii) the cell wall composition of Gram-positive bacteria conferring
46
47 21 resistance to lysis. In addition, the presence of capsules in different species (*S. pneumoniae*,
48
49 22 *Haemophilus influenzae*, *Klebsiella pneumoniae*) may also explain the lower performance of
50
51 23 MALDI-TOF.
52
53
54
55
56
57
58
59
60

1
2
3 1 The performance of MALDI-TOF for the identification of fungi in blood culture is low. In
4
5 2 one study (Ferreira, *et al.*, 2010), no fungi (0/18) were identified at the species level and only
6
7 3 one at the genus level. This poor performance is attributed to the relatively low load of fungi
8
9 4 observed in positive blood culture and to the presence of residual blood protein which co-
10
11 5 migrates during the MALDI-TOF assay, which impairs the performance of the diagnostic
12
13 6 algorithm. To circumvent this detrimental effect, a reference database of fungi obtained from
14
15 7 blood culture spiked with fungi was established to obtain correct identification at the species
16
17 8 level (Marinach-Patrice, *et al.*, 2010).

18
19
20
21
22
23 9 Limitation of the MALDI-TOF identification was also observed for mixed bloodstream
24
25 10 infection, where only one bacterium could be identified (La Scola & Raoult, 2009,
26
27 11 Moussaoui, *et al.*, 2010, Szabados, *et al.*, 2011).

28
29
30
31 12 The impact of the broth on the spectral quality and thus on the rate of identification has been
32
33 13 analysed in several studies. The first published studies have used bottles adapted to the
34
35 14 BACTEC system (Becton Dickinson, Franklin Lakes, NJ, USA). More recently, bottles with
36
37 15 and without charcoal adapted to Bact/ALERT automated instruments have been tested
38
39 16 (bioMérieux, Marcy l'Etoile, France). In this system, charcoal is used to inactivate
40
41 17 antimicrobial agents present in patient's blood. In one study, the rate of identification using
42
43 18 MALDI-TOF was 30% without charcoal and decrease to only 8% when charcoal was present
44
45 19 (Szabados, *et al.*, 2011). Another study compared the performance of identification using
46
47 20 MALDI-TOF with positive blood culture obtained from three automated systems: BACTEC,
48
49 21 VERSATREK (Trek diagnostic Systems, Cleveland, USA) and BactT/ALERT. The rate of
50
51 22 direct identification of bacteria cultured in these 3 automated blood culture devices were 76%,
52
53 23 69% and 62% for the investigated samples, respectively (Romero-Gomez & Mingorance,
54
55 24 2011).

1
2
3 1 The importance of the protein extraction method was compared with the so-called intact cell
4
5 2 method, which consist in the direct deposition on MALDI plate of bacterial pellet obtained
6
7
8 3 from positive blood culture. In one study, the performance of MALDI-TOF identification at
9
10 4 the species level was 47% for the intact cell method compared to 76% for the protein
11
12 5 extraction method (Ferreira, *et al.*, 2010). The simple extraction method used in this study
13
14 6 improves significantly the performance of MALDI-TOF identification rate. In our laboratory,
15
16 7 we now use this approach on a routine basis, with a turnaround time estimated to about 1
17
18 8 hour. However, to be efficient and have such a low turnaround time, there is a need to
19
20 9 prioritize identification of bacteria isolated from blood cultures over other routine applications
21
22 10 of the MALDI-TOF. Thus, this activity somehow delays other microbial identifications, as
23
24 11 shown in Figure 4.

25
26
27
28
29
30 12 In conclusion, the application of MALDI-TOF identification to microorganism pellets
31
32 13 obtained from positive blood culture allows a rapid identification of microorganisms growing
33
34 14 in blood culture which is important for the management of bloodstream infections.

35 36 37 38 15 **Urine**

39
40
41 16 Since the bacterial amount in urine taken from patients with urinary tract infection is often \geq
42
43 17 10^5 bacteria/ml, the use of MALDI-TOF directly on urine has been investigated by numerous
44
45 18 groups. However, since only about 1 to 2 μ l of liquid may be deposited on the MALDI-TOF
46
47 19 microplate, results were not accurate when untreated urine are directly deposited and thus
48
49 20 various pre-treatment steps have been tested with different outcomes. Using two consecutive
50
51 21 centrifugation steps (low speed to remove leucocytes and high speed to collect the bacteria),
52
53 22 Ferreira *et al.* could accurately identify as much as 94.2% of bacteria (Ferreira, *et al.*, 2010).
54
55 23 However, they only included in their study urine with $> 10^5$ bacteria/ml. When investigating a
56
57 24 simplified protocol in our laboratory for the identification of *E. coli* (single centrifugation
58
59
60

1
2
3 1 step), the results was acceptable when the bacterial concentration was of 10^7 and 10^8
4
5 2 bacteria/ml with 69% and 70% of samples being accurately identified at the species level
6
7
8 3 (score > 2). However, the yield was poor with lower bacterial load (Figure 5). Given the huge
9
10 4 amount of urine processed on a daily basis, the low value of early identification and the
11
12 5 requirement of bacterial isolation in pure culture for antibiotic susceptibility testing, it appears
13
14 6 that the MALDI-TOF on urine is not cost-effective and not efficient enough to be
15
16 7 implemented directly on urine samples. Indeed, since most urinary isolates are *E. coli* (> 80%
17
18 8 among uncomplicated cystitis occurring in young women and about 50% in complicated
19
20 9 urinary tract infections), the use of a chromogenic agar (i.e. Urid, bioMérieux) coupled with
21
22 10 simple phenotypic tests such as indole represents a simpler way to identify most strains.
23
24 11 MALDI-TOF will then be mainly used to identify the remaining species starting from
25
26 12 colonies.
27
28
29
30
31

32 **Maintenance and quality controls**

33
34
35 14 The MALDI-TOF MS is increasingly used in clinical diagnostic laboratory for microbial
36
37 15 identification with reliable results for bacterial identification at species level.
38
39
40

41 16 MALDI-TOF results may however be impaired by problems arising during extraction, for
42
43 17 instances (i) when testing encapsulated bacteria (*Streptococcus pneumoniae*, *Klebsiella*
44
45 18 *pneumoniae*), (ii) when testing bacteria such as *Streptomyces*, that exhibit a particular cell
46
47 19 wall that reduces the yield of protein extraction, (iii) when the extraction protocol is not
48
49 20 properly conducted, or (iv) when the reagents used for extraction are outdated or impaired by
50
51 21 inadequate storage. Problems (i) and (ii), due to intrinsic bacterial properties, may only be
52
53 22 circumvented by the development of specific extraction protocols and problems (iii) and (iv)
54
55 23 might be prevented by an adequate quality program. The performance of the extraction step
56
57 24 and of the MALDI-TOF mass spectrometer may be checked by routinely testing a few
58
59
60

1
2
3 1 selected bacterial strains, for which spectra are available in the database. This control should
4
5 2 ideally be done in parallel with and without a specific extraction step. We thus implemented
6
7 3 in our laboratory routine internal quality controls that test the quality of the extraction step on
8
9 4 two different bacterial species (*E. coli* ATCC 25922 and *S. aureus* ATCC 25923). To set-up
10
11 5 this quality control, we first investigated the reproducibility of the extraction step (see Figure
12
13 6 2 & paragraph on reproducibility). This allowed us to define conserved peaks [peaks present
14
15 7 in 10/10 replicates]. Then, we routinely tested once a week both bacterial species. Since score
16
17 8 values were always above 2 and to obtain a better expression of the quality of the extraction,
18
19 9 we decided to report the proportion of conserved peaks detected, considering a peak as
20
21 10 present only when its intensity was above 200. Indeed, the rate of detection of conserved
22
23 11 peaks reflects not only the quality of the sample but also the protein yield and the spectral
24
25 12 quality (Figure 6).

26
27
28
29
30
31
32 13 MALDI-TOF results may also be impaired by inadequate deposit of the sample on the
33
34 14 microplate and by poor cleaning of the microplate between runs. Inadequate deposit of
35
36 15 samples is relatively rare when starting from bacterial colonies and the learning curve is rapid
37
38 16 with most laboratory technicians being already experts in depositing appropriate amount of
39
40 17 bacteria after only a few training days. However, erroneous identification may occur due to
41
42 18 well inversions, especially when large series are processed and when stress is increased by
43
44 19 human resources shortage.

45
46
47
48
49
50 20 Poor cleaning of the microplate is a problem only encountered by Bruker users since
51
52 21 Shimadzu users will use disposable MALDI-TOF plates. Bruker commonly propose to use
53
54 22 trichloroacetic acid (TFA) or guanidinium to clean microplates between usages. Since TFA is
55
56 23 associated with significant occupational hazard (eye, skin and respiratory toxicity), we used in
57
58 24 our laboratory an alternative protocol in order to clean MALDI-TOF microplate. This
59
60 25 protocol, initially proposed by Bruker, which mainly uses ethanol and mechanical cleaning of

1 target plates, is however insufficient to properly clean MALDI-TOF microplates. Indeed,
2 when investigating cleaned plates by testing them only in presence of matrix, we could obtain
3 some accurate identification with score > 2 and corresponding to the same bacterial species
4 investigated the day before. Such accurate identifications obtained after plate cleaning could
5 rarely correspond to wells where some material was still present (Figure 7A, wells C4, E3 and
6 E4), but also occurred in apparently clean wells. Thus, a systematic control of the microplates
7 should be done and the cleaning protocol adapted when necessary. Noteworthy, disposable
8 microplates are now also available for Bruker users.

9 MALDI-TOF results may also be impaired by technical problems and/or poor maintenance of
10 the MALDI-TOF device. To identify possible technical problems and to recalibrate the mass
11 spectrometry apparatus, we routinely use in Lausanne the calibration control proposed by
12 Bruker. This control (coined BTS) consists of lyophilised *E. coli* extracts and 2 supplementary
13 proteins, RNase A and myoglobin, which respectively exhibit peaks at 13683 and 16952 m/z
14 (Figure 7B). Finally, in the future, external quality control should be implemented.

15 Appropriate maintenance (Figure S1) is also essential to warrant accurate bacterial
16 identification. Vacuum failure, and thus MALDI-TOF MS functional disturbance (see figure
17 1), might be observed due to the presence of dust on plastic joints or to the ageing of these
18 plastic joints (Figure S1 C and D). Dust exposure of the MALDI-TOF apparatus might be
19 reduced by placing the mass spectrometer in a quiet area, without draft. Carbonisation of
20 bacteria embedded in the matrix material following each laser pulse is also a source of
21 concern, since the laser source may be soiled (Figure S1 D). With the Bruker instrument, the
22 rate of dirtiness present on the laser source may be indirectly estimated according to the
23 number of shots needed to obtain a correct identification. Maintenance should ideally be done
24 before the dirtiness rate reach 80%, i.e about 4 times a year if 3 to 5 microplates are tested per

1 day. Of course, frequency of maintenance of the MALDI-TOF should be increased if the
2 apparatus is heavily used or located in a crowded/dusty area.

3 Despite adequate maintenance and correct procedures, some microbial groups will repeatedly
4 be misidentified due to poor content of some databases. Thus, it appears critical not only to
5 implement a quality control program targeting routine procedure but also to incrementally
6 improve the quality of the database. In conclusion, quality controls might help to improve the
7 quality of proteins extraction, MALDI-TOF analysis and completeness of databases. This will
8 thus further improve the accuracy and usefulness of MALDI-TOF.

9 **Accuracy, Time and Cost effectiveness**

10 The MALDI-TOF MS approach represents a new tool that has the potential to replace
11 conventional identification techniques for a majority of routine isolates encountered in clinical
12 microbiology laboratories. The performance of the MALDI-TOF MS approach has been
13 compared in several studies (Seng, *et al.*, 2009, Bizzini, *et al.*, 2010, Cherkaoui, *et al.*, 2010,
14 van Veen, *et al.*, 2010) with multiple routine phenotypic identification methods, such as semi-
15 automated Gram staining (Aerospray Wescor® ; Elitech), catalase and oxidase determination
16 tests, automated identification by Vitek ® (bioMérieux), the Api Anaérobie BioMérieux®
17 identification strip for anaerobes (bioMérieux), the Slidex Staph plus system (bioMérieux).
18 These studies showed that the MALDI-TOF technique has a high accuracy for most microbial
19 identifications and performed equally as well as or better than conventional techniques. For
20 instance, van Veen *et al.* showed that significantly more bacterial isolates could be identified
21 to the species level by MALDI-TOF MS, with a special higher performance for staphylococci
22 and bacteria from the HACCEK group (van Veen, *et al.*, 2010). Similarly, Bader *et al.* have
23 shown that identification of yeast species with MALDI-TOF MS systems gave an overall

1 species identification rate (97.9 % for Bruker and 96.1% for Shimadzu) that was comparable
2 to the one obtained with the biochemical tests (96.9%) (Bader, *et al.*, 2010).

3 The most striking differences between MALDI-TOF technique and conventional
4 identification methods are observed in the estimated time and costs required for sample
5 identification. The cost of bacterial identification by MALDI-TOF MS was estimated to
6 represent only 17-32% (around €1.43/sample) of the costs of conventional identification
7 methods (around €4.6-8.23/sample) in the study performed by Seng *et al.* (Seng, *et al.*, 2009),
8 which is supported by at least two other prospective studies (Bizzini, *et al.*, 2010, Cherkaoui,
9 *et al.*, 2010). Cherkaoui *et al.* have shown that the reagents required for phenotypic
10 identification using modern automated platforms costs at least around \$10 per isolate whereas
11 MS-required reagents do not exceed \$0.50 (Cherkaoui, *et al.*, 2010). The expensive prices of
12 MS instruments are comparable to other common bacteriology laboratory equipment such as
13 automated blood culture and 16S sequencing devices but the running costs are significantly
14 cheaper than those of conventional identification methods. Thus, in our laboratory, we
15 estimated that the reagents costs spared during a year are of approximately 40'000 euros
16 (Table S2). Of course, this cost analysis did not include the cost of maintenance, neither for
17 MALDI-TOF nor for automated phenotypic identification systems such as Vitek.

18 Compared to conventional identification methods, MALDI-TOF has been shown to confer in
19 most cases a significant gain of both technician working time (preanalytical procedure to
20 prepare samples) and turnaround time (automated analytical procedure to obtain results).

21 The time needed for bacterial identification from intact cells was 6-8.5 min versus 5-48h for
22 conventional identification as estimated by Seng *et al.* (Seng, *et al.*, 2009). When an
23 extraction step is required, Bizzini *et al.* have estimated that the extraction procedure for a
24 single sample takes approximately 6 min, a time per sample that is further reduced during

1
2
3 1 batch processing (Bizzini, *et al.*, 2010). The time effectiveness gained with MALDI-TOF
4
5 2 identification compared to classical identification approaches is even more accentuated when
6
7 3 several isolates are analysed in parallel. As reported by Cherkaoui *et al.*, the analysis of 10
8
9 4 isolates in parallel can be accomplished in less than 15 min with limiting working time by MS
10
11 5 whereas more than 360 min would be required on an automated system with more hands-on
12
13 6 time for each isolate (Cherkaoui, *et al.*, 2010) demonstrating that MALDI-TOF MS provide a
14
15 7 reduction of both working and turnaround times. Regarding yeast identification by MALDI-
16
17 8 TOF MS, Marklein *et al.* showed that this technique required minimal time for technicians to
18
19 9 process yeast samples for analysis and to interpret the results (Marklein, *et al.*, 2009). The
20
21 10 MALDI-TOF identification procedure from single yeast colonies on the agar plate was
22
23 11 generally completed within 10 min per isolate and within 3h for 96 samples. In contrast, the
24
25 12 identification of germ tube-negative *Candida* species by phenotypic methods can require
26
27 13 incubation periods of up to 72h, a significant longer turnaround time compared to MALDI-
28
29 14 TOF. Molecular approaches have been or are currently under development to provide efficient
30
31 15 identification of yeasts with a more rapid and reliable efficiency than classical phenotypic
32
33 16 methods. However, high-resolution DNA-based molecular techniques such as 26S rRNA or
34
35 17 internal transcriber spacer DNA sequencing and real-time PCR assays are expensive and
36
37 18 time-consuming and appear in most cases less convenient than MALDI-TOF MS for routine
38
39 19 laboratory identifications (Schabereiter-Gurtner, *et al.*, 2007, Montero, *et al.*, 2008, Seyfarth,
40
41 20 *et al.*, 2008). Nucleic acid-based identification strategies suffer problematic limitations in
42
43 21 terms of (1) technical problems (inhibitory compounds, contamination, separate areas for
44
45 22 sample preparation/amplification/analysis), (2) reagent and labour costs, (3) spectrum of
46
47 23 species identification in a single assay often limited to a few individual species, and (4) much
48
49 24 longer turnaround time than MS. Thus such lengthier, costlier and labour-intensive alternative
50
51 25 to MALDI-TOF MS are usually reserved for the identification of the small minority of
52
53
54
55
56
57
58
59
60

1 isolates not identified by MS alone or by other conventional phenotypic and/or biochemical
2 identification approaches.

3 **Taxonomy and microbial typing**

4 **Taxonomic usefulness of MALDI-TOF MS**

5 Taxonomy is the systematic classification of organisms based on their phenotypic, genetic and
6 phylogenetic characteristics. Thus, various phenotypic approaches (morphology, biochemical
7 reactions, and sugar assimilation) have been used by microbiologists to classify
8 microorganisms. However, genome analysis through sequencing of bacterial genes or of the
9 entire genome currently represents the gold-standard of microbial taxonomy, although it
10 should always be confronted to phenotypic traits in a polyphasic approach. MALDI-TOF MS
11 represent an additional approach to classify microorganisms based on phenotypic traits. As
12 previously shown in several studies mentioned in this review, MALDI-TOF MS systems give
13 accurate and reproducible results at the species level that are in most cases concordant with
14 genomic identification methods and consequently, MALDI-TOF has the potential to be used
15 in polyphasic taxonomy. For instance, in contrast to housekeeping genes sequencing such as
16 16SrRNA that provide taxonomical data on a single gene at a time, MALDI-TOF MS
17 fingerprints provide information about multiple protein components that characterize a
18 microorganism. In addition, MALDI-TOF fingerprints provide data of both the presence
19 (conservation/divergence) and the intensity (expression level) that together compose a two
20 dimensional taxonomical asset which offer a better discriminative resolution for
21 microorganism classification.

22 **Microbial typing and identification at the subspecies level**

23 MALDI-TOF MS allows identification of microbes at the species level and sometimes at the
24 subspecies level but several studies have shown that the requirements for MALDI-TOF MS-
25 dependent microbial typing are different and more complex than those required for routine

1
2
3 1 microbial identification. This is a challenge for clinical laboratories that want to use MALDI-
4
5 2 TOF MS for routine strain typing. Relatively few biomarkers (5 to 10 peaks) are usually
6
7
8 3 required for the identification of microbial isolates at the species level whereas a much larger
9
10 4 number of reproducible peaks is needed for subspecies identification (Dieckmann, *et al.*,
11
12 5 2008). Many studies cited in this review using conventional MALDI-TOF procedure could
13
14
15 6 not directly identify taxonomic entities like species or subspecies with an accuracy of 100%
16
17 7 without the assistance of DNA-based methods. Microbial typing and thus microbial
18
19 8 characterization at the subspecies level required very different sample preparation and
20
21 9 analytical procedures (Murray, 2010). As mentioned previously in this review, accurate
22
23
24 10 sample preparation is generally unnecessary for microorganism identification but for strain
25
26 11 typing and subspecies identification, a rigorous optimization of testing parameters appears to
27
28
29 12 be crucial. The challenge is to obtain a sufficient number of reproducible markers with
30
31 13 specificities below species-level specificity (Rupf, *et al.*, 2005, Vargha, *et al.*, 2006,
32
33 14 Dieckmann, *et al.*, 2008). For instance, the sample preparation procedure (whole cell or
34
35 15 protein extraction), the protein concentration, the type of matrix, the sample:matrix ratio, the
36
37 16 concentration of acid added to the matrix and the growth medium are examples of technical
38
39 17 parameters that can have a significant influence on the MALDI-TOF spectral profile of
40
41 18 biomarkers (Vargha, *et al.*, 2006, Dieckmann, *et al.*, 2008).

42
43
44
45
46 19 The choice of analysis solutions used to process mass spectra can have a significant impact on
47
48 20 the power of discrimination and thus on the ability to distinguish closely related isolates.
49
50 21 Maximizing reproducibility is also critical for accurate microbial characterization. One of the
51
52 22 major limitations of MALDI-TOF-based microbial typing is primarily due to the algorithmic
53
54 23 methods used to analyse the protein profiles. Several similarity coefficients can be used to
55
56 24 determinate level of similarities. Some account only for peak presence/absence such as the
57
58 25 Dice similarity coefficient, whereas others take also in consideration the peak intensities, such
59
60

1
2
3 1 as cosine and Pearson product-moment correlation coefficients. The chosen similarity
4
5
6 2 coefficient affects the reproducibility and the discriminatory power of the method. Several
7
8 3 studies have demonstrated that the Pearson coefficient appears to be more adequate for the
9
10 4 correct classification of microbial isolates. A study by Giebel *et al.* showed that the Pearson
11
12 5 product-moment correlation coefficient permitted a more accurate classification of
13
14 6 *Enterococcus* spp. isolates than the Dice similarity coefficient (Giebel, *et al.*, 2008).
15
16 7 Similarly, the use of the Pearson correlation coefficient allowed a 28% increase in the rate of
17
18 8 correct classification of *E.coli* isolates (Giebel, *et al.*, 2010). Using optimal sample
19
20 9 preparation and MALDI conditions for discrimination at the strain level and by using the
21
22 10 Pearson coefficient, Vargha *et al.* have shown that MALDI-TOF MS offered a better
23
24 11 discriminatory power than 16S rRNA gene sequencing for the classification at the subspecies
25
26 12 level of *Arhtrobacter* isolates (Vargha, *et al.*, 2006). For instance, members of the *A.*
27
28 13 *globiformis* cluster have 99-100% sequence similarity whereas MALDI-TOF MS similarity is
29
30 14 60-95%.

31
32
33
34
35
36
37 15 In some cases, the identification of multiple or single unique subspecies biomarkers have been
38
39 16 used to discriminate closely related microbial isolates exhibiting highly similar mass
40
41 17 signatures. For instance, five unique and conserved biomarkers ions were identified in
42
43 18 environmental *E. coli* isolates from avian but not from human sources (Siegrist, *et al.*, 2007).
44
45 19 Similarly, several *Listeria monocytogenes* serotypes could be separated using discriminating
46
47 20 peaks (Barbuddhe, *et al.*, 2008).
48
49
50

51
52 21 Despite an increased level of complexity required for microbial subspecies classification,
53
54 22 several published studies support the observation that MALDI-TOF MS represents a new
55
56 23 promising technological approach for the classification of clinical and environmental isolates.
57
58 24 Dieckmann *et al.* have successfully classified 126 isolates of *Salmonella* at the species and
59
60 25 subspecies levels by optimizing a procedure that allowed them to obtain more than 300

1
2
3 1 biomarker peaks ranging from 2 to > 35 kDa (Dieckmann, *et al.*, 2008). They found that out
4
5 2 of three matrix mixtures, SA produced the most informative spectra by providing a significant
6
7 3 increase of high molecular mass peaks with important subspecies specificity. In addition,
8
9 4 simple clustering of mass data from bacterial fingerprints did not initially provide a clear
10
11 5 discrimination of the strains at the subspecies level and a bioinformatic approach recently
12
13 6 published by Teramoto *et al.* had to be used (Teramoto, *et al.*, 2007). The approach is a new
14
15 7 phylogenetic classification method based on ribosomal protein profiling by MALDI-TOF MS
16
17 8 using the bioinformatics-based method for rapid identification of bacteria published by
18
19 9 Demirev and co-workers (Demirev, *et al.*, 1999). Using this approach, the result of the
20
21 10 classification of several *Pseudomonas putida* strains including different biovars was in
22
23 11 agreement with the *gyrB* gene sequences-based classification.
24
25
26
27
28
29

30 12 The determination of serotypes of Shiga toxin-producing *E. coli* isolates has been achieved by
31
32 13 constructing prototype spectra representing different serotype groups (Karger, *et al.*, 2011).
33
34 14 The prototype spectra were generated by removing masses with low discriminative
35
36 15 significance, which is a process comparable to the generation of super-spectra proposed by
37
38 16 the SARAMIS software. The generation of prototype spectra allowed a reduction of incorrect
39
40 17 assignments down to 0.7% compared to the 31% incorrect assignments observed when
41
42 18 unfiltered mass spectra were used. Unlike restriction fragment length polymorphism analysis,
43
44 19 this analytical methodology could not achieve a differentiation below the serotype level.
45
46
47
48
49

50 20 The typing of several microorganisms, such as *Staphylococcus* and *Listeria* species, for
51
52 21 epidemiological studies require the use of various conventional techniques such as pulsed-
53
54 22 field gel electrophoresis (PFGE), amplified fragment length polymorphism analysis and
55
56 23 multilocus sequence analysis (MLSA). These gold-standard techniques provide accurate
57
58 24 classification of microorganism but suffer from important time and cost investments. For
59
60 25 instance, only a few hours are required to obtain results by MALDI-TOF MS whereas several

1 days are necessary to collect PFGE data. In addition, these methods are technically relatively
2 complex and have to be usually performed by experienced technicians.

3 Several *Staphylococcus* studies have developed standardized methods to achieve reliable and
4 reproducible species level identification and sub-typing from MALDI-TOF fingerprints
5 (Edwards-Jones, *et al.*, 2000, Walker, *et al.*, 2002, Jackson, *et al.*, 2005). When performed
6 under careful experimental conditions, MALDI-TOF MS has been used to discriminate
7 between methicillin-resistant (MRSA) and methicillin-susceptible *S. aureus* strains and to
8 subtype MRSA strains. Thus, compared to conventional antimicrobial susceptibility test
9 methods or gene sequencing techniques, these studies have demonstrated that MALDI-TOF
10 MS represents a fast and cheap approach to accurately differentiate *S. aureus* strains.
11 Unfortunately, no comparison of MALDI-TOF MS with PFGE has been done to demonstrate
12 that these two methods would give similar results. However, Barbuddhe *et al.* have used
13 MALDI-TOF to accurately identify 146 strains of different *Listeria* species and correctly
14 classified all *L. monocytogenes* serotypes in agreement with PFGE, which is one of the most
15 common subtyping technique used to classify *L. monocytogenes* serotypes (Barbuddhe, *et al.*,
16 2008). Similarly, Fujinami *et al.* have demonstrated that MALDI-TOF MS and PGFE gave
17 similar accurate identification of epidemiologic *Legionella* strains (Fujinami, *et al.*, 2010).
18 Hazen *et al.* have demonstrated that MALDI-TOF MS could be used to discriminate between
19 several *Vibrio parahaemolyticus* strains in replacement of PFGE or multilocus sequence
20 analysis (MLSA) (Hazen, *et al.*, 2009). Thus these studies showed that MALDI-TOF
21 represents a new promising alternative approach to other demanding conventional methods
22 such as PFGE and MLSA for microbial subtyping.

23 Overall, the ultimate goal would be to use MALDI-TOF for a rapid prospective typing at the
24 time of identification which should significantly benefit to hospital epidemiology and to
25 infection control measures that have to be applied to prevent dissemination of pathogens.

1
2
3 1 Three recent studies have demonstrated that by applying subtle minor changes in the setup
4
5 2 generally used in routine diagnostics, MALDI-TOF MS allowed a reproducible discrimination
6
7 3 of major MRSA lineages (Wolters, *et al.*, 2011), an identification of *Salmonella enterica*
8
9 4 subsp. *enterica* serovars (Dieckmann & Malorny, 2011) and a differentiation between *cfiA*-
10
11 5 negative and *cfiA*-positive *Bacteroidis fragilis* isolates (Wybo, *et al.*, 2011). These studies
12
13 6 demonstrate that for several microbial species, minor changes in standardized procedures such
14
15 7 as improved algorithm and user-friendly softwares applied in routine diagnostics will allow
16
17 8 the use of MALDI-TOF MS for rapid and inexpensive microbial typing. This could
18
19 9 significantly improve the approaches currently used to monitor epidemiological outbreaks and
20
21 10 pathogens surveillance.
22
23
24
25
26
27

28 11 **Conclusion**

29
30
31 12 MALDI-TOF represents a very appealing new microbial identification technology that is
32
33 13 efficient, rapid, cheap and easy of use. This explains why MALDI-TOF MS can be
34
35 14 successfully used in clinical diagnostic laboratory for microbial identification starting from
36
37 15 subcultures on agar plates and broth media but also directly from positive blood cultures and
38
39 16 to a lesser extent from clinical samples such as urine. The application of MALDI-TOF at the
40
41 17 subspecies level in typing is promising but still needs further improvement including
42
43 18 instrument sensitivity, database quality and post-run analysis methods. Overall, a MALDI-
44
45 19 TOF MS will be soon present in most diagnostic laboratories since despite the significant cost
46
47 20 of the instrument and for maintenance, running costs and consumables are much lower than
48
49 21 those for other conventional methods rendering this technology a worthy quantum leap tool.
50
51
52
53
54

55 22 **Acknowledgements**

56
57
58
59
60

1 We thank Myriam Corthesy for technical support. G. Greub is supported by the Leenards
2 Foundation through a career award entitled “Bourse Leenards pour la relève académique en
3 médecine clinique à Lausanne”.

4 **References**

- 5 Aebersold R & Mann M (2003) Mass spectrometry-based proteomics. *Nature* **422**: 198-207.
- 6 Alanio A, Beretti JL, Dauphin B, *et al.* (2010) Matrix-assisted laser desorption ionization time-of-flight
7 mass spectrometry for fast and accurate identification of clinically relevant *Aspergillus* species. *Clin*
8 *Microbiol Infect.*
- 9 Anhalt JP & Fenselau C (1975) Identification of bacteria using mass spectrometry. *Anal Chem* **47**: 219-
10 225.
- 11 Arnold RJ, Karty JA, Ellington AD & Reilly JP (1999) Monitoring the growth of a bacteria culture by
12 MALDI-MS of whole cells. *Anal Chem* **71**: 1990-1996.
- 13 Bader O, Weig M, Taverner-Ghadwal L, Lugert R, Gross U & Kuhns M (2010) Improved clinical
14 laboratory identification of human pathogenic yeasts by matrix-assisted laser desorption ionization
15 time-of-flight mass spectrometry. *Clin Microbiol Infect.*
- 16 Barbuddhe SB, Maier T, Schwarz G, *et al.* (2008) Rapid identification and typing of listeria species by
17 matrix-assisted laser desorption ionization-time of flight mass spectrometry. *Appl Environ Microbiol*
18 **74**: 5402-5407.
- 19 Bernardo K, Pakulat N, Macht M, *et al.* (2002) Identification and discrimination of *Staphylococcus*
20 *aureus* strains using matrix-assisted laser desorption/ionization-time of flight mass spectrometry.
21 *Proteomics* **2**: 747-753.
- 22 Bessedé E, Angla-Gre M, Delagarde Y, Sep Hieng S, Menard A & Megraud F (2011) Matrix-assisted
23 laser-desorption/ionization biotyper: experience in the routine of a University hospital. *Clinical*
24 *microbiology and infection : the official publication of the European Society of Clinical Microbiology*
25 *and Infectious Diseases* **17**: 533-538.
- 26 Bizzini A & Greub G (2010) Matrix-assisted laser desorption ionization time-of-flight mass
27 spectrometry, a revolution in clinical microbial identification. *Clin Microbiol Infect* **16**: 1614-1619.
- 28 Bizzini A, Durussel C, Bille J, Greub G & Prod'homme G (2010) Performance of matrix-assisted laser
29 desorption ionization-time of flight mass spectrometry for identification of bacterial strains routinely
30 isolated in a clinical microbiology laboratory. *J Clin Microbiol* **48**: 1549-1554.
- 31 Bizzini A, Jaton K, Romo D, Bille J, Prod'homme G & Greub G (2011) Matrix-assisted laser desorption
32 ionization-time of flight mass spectrometry as an alternative to 16S rRNA gene sequencing for
33 identification of difficult-to-identify bacterial strains. *Journal of clinical microbiology* **49**: 693-696.
- 34 Blondiaux N, Gaillot O & Courcol RJ (2010) [MALDI-TOF mass spectrometry to identify clinical
35 bacterial isolates: evaluation in a teaching hospital in Lille]. *Pathol Biol (Paris)* **58**: 55-57.
- 36 Cain TC, Lubman DM & Webber WJ (1994) Differentiation of bacteria using protein profiles from
37 MALDI-TOF/MS. *Rapid Commun Mass Spectrom* **8**.
- 38 Carbonnelle E, Beretti JL, Cottyn S, Quesne G, Berche P, Nassif X & Ferroni A (2007) Rapid
39 identification of *Staphylococci* isolated in clinical microbiology laboratories by matrix-assisted laser
40 desorption ionization-time of flight mass spectrometry. *Journal of clinical microbiology* **45**: 2156-
41 2161.
- 42 Carbonnelle E, Mesquita C, Bille E, *et al.* (2010) MALDI-TOF mass spectrometry tools for bacterial
43 identification in clinical microbiology laboratory. *Clin Biochem.*
- 44 Chen HY & Chen YC (2005) Characterization of intact *Penicillium* spores by matrix-assisted laser
45 desorption/ionization mass spectrometry. *Rapid Commun Mass Spectrom* **19**: 3564-3568.

- 1
2
3 1 Cherkaoui A, Hibbs J, Emonet S, Tangomo M, Girard M, Francois P & Schrenzel J (2010) Comparison
4 2 of two matrix-assisted laser desorption ionization-time of flight mass spectrometry methods with
5 3 conventional phenotypic identification for routine identification of bacteria to the species level. *J Clin*
6 4 *Microbiol* **48**: 1169-1175.
- 7 5 Christner M, Rohde H, Wolters M, Sobottka I, Wegscheider K & Aepfelbacher M (2010) Rapid
8 6 identification of bacteria from positive blood culture bottles by use of matrix-assisted laser
9 7 desorption-ionization time of flight mass spectrometry fingerprinting. *J Clin Microbiol* **48**: 1584-1591.
- 10 8 Claydon MA, Davey SN, Edwards-Jones V & Gordon DB (1996) The rapid identification of intact
11 9 microorganisms using mass spectrometry. *Nat Biotechnol* **14**: 1584-1586.
- 12 10 Conway GC, Smole SC, Sarracino DA, Arbeit RD & Leopold PE (2001) Phyloproteomics: species
13 11 identification of Enterobacteriaceae using matrix-assisted laser desorption/ionization time-of-flight
14 12 mass spectrometry. *J Mol Microbiol Biotechnol* **3**: 103-112.
- 15 13 Cotter RJ (1997) *Time-of-flight mass spectrometry: instrumentation and applications in biological*
16 14 *research*. Washington DC.
- 17 15 Dai Y, Li L, Roser DC & Long SR (1999) Detection and identification of low-mass peptides and proteins
18 16 from solvent suspensions of Escherichia coli by high performance liquid chromatography
19 17 fractionation and matrix-assisted laser desorption/ionization mass spectrometry. *Rapid Commun*
20 18 *Mass Spectrom* **13**: 73-78.
- 21 19 Demirev PA, Ho YP, Ryzhov V & Fenselau C (1999) Microorganism identification by mass
22 20 spectrometry and protein database searches. *Anal Chem* **71**: 2732-2738.
- 23 21 Dieckmann R & Malorny B (2011) Rapid screening of epidemiologically important Salmonella enterica
24 22 subsp. enterica serovars using Whole-Cell MALDI-TOF mass spectrometry. *Appl Environ Microbiol*.
- 25 23 Dieckmann R, Helmuth R, Erhard M & Malorny B (2008) Rapid classification and identification of
26 24 salmonellae at the species and subspecies levels by whole-cell matrix-assisted laser desorption
27 25 ionization-time of flight mass spectrometry. *Appl Environ Microbiol* **74**: 7767-7778.
- 28 26 Domon B & Aebersold R (2006) Mass spectrometry and protein analysis. *Science* **312**: 212-217.
- 29 27 Dupont C, Sivadon-Tardy V, Bille E, *et al.* (2010) Identification of clinical coagulase-negative
30 28 staphylococci, isolated in microbiology laboratories, by matrix-assisted laser desorption/ionization-
31 29 time of flight mass spectrometry and two automated systems. *Clin Microbiol Infect* **16**: 998-1004.
- 32 30 Edwards-Jones V, Claydon MA, Evason DJ, Walker J, Fox AJ & Gordon DB (2000) Rapid discrimination
33 31 between methicillin-sensitive and methicillin-resistant Staphylococcus aureus by intact cell mass
34 32 spectrometry. *J Med Microbiol* **49**: 295-300.
- 35 33 Emonet S, Shah HN, Cherkaoui A & Schrenzel J (2010) Application and use of various mass
36 34 spectrometry methods in clinical microbiology. *Clin Microbiol Infect* **16**: 1604-1613.
- 37 35 Erhard M, Hipler UC, Burmester A, Brakhage AA & Wostemeyer J (2008) Identification of
38 36 dermatophyte species causing onychomycosis and tinea pedis by MALDI-TOF mass spectrometry. *Exp*
39 37 *Dermatol* **17**: 356-361.
- 40 38 Fenselau C & Demirev PA (2001) Characterization of intact microorganisms by MALDI mass
41 39 spectrometry. *Mass Spectrom Rev* **20**: 157-171.
- 42 40 Ferreira L, Sanchez-Juanes F, Munoz-Bellido JL & Gonzalez-Buitrago JM (2010) Rapid method for
43 41 direct identification of bacteria in urine and blood culture samples by matrix-assisted laser
44 42 desorption ionization time-of-flight mass spectrometry: intact cell vs. extraction method. *Clin*
45 43 *Microbiol Infect*.
- 46 44 Ferreira L, Sanchez-Juanes F, Gonzalez-Avila M, Cembrero-Fucinos D, Herrero-Hernandez A,
47 45 Gonzalez-Buitrago JM & Munoz-Bellido JL (2010) Direct identification of urinary tract pathogens from
48 46 urine samples by matrix-assisted laser desorption ionization-time of flight mass spectrometry. *J Clin*
49 47 *Microbiol* **48**: 2110-2115.
- 50 48 Ferreira L, Sanchez-Juanes F, Guerra IP, Garcia Garcia MI, Sanchez JE, Gonzalez-Buitrago JM & Bellido
51 49 JL (2010) Microorganisms Direct Identification from Blood Culture by Maldi-Tof Mass Spectrometry.
52 50 *Clin Microbiol Infect*.
- 53
54
55
56
57
58
59
60

- 1
2
3 1 Ferroni A, Suarez S, Beretti JL, *et al.* (2010) Real-time identification of bacteria and *Candida* species in
4 2 positive blood culture broths by matrix-assisted laser desorption ionization-time of flight mass
5 3 spectrometry. *J Clin Microbiol* **48**: 1542-1548.
- 7 4 Fujinami Y, Kikkawa HS, Kurosaki Y, Sakurada K, Yoshino M & Yasuda J (2010) Rapid discrimination of
8 5 *Legionella* by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. *Microbiol*
9 6 *Res.*
- 10 7 Giebel R, Worden C, Rust SM, Kleinheinz GT, Robbins M & Sandrin TR (2010) Microbial fingerprinting
11 8 using matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS)
12 9 applications and challenges. *Adv Appl Microbiol* **71**: 149-184.
- 14 10 Giebel RA, Fredenberg W & Sandrin TR (2008) Characterization of environmental isolates of
15 11 *Enterococcus* spp. by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.
16 12 *Water Res* **42**: 931-940.
- 17 13 Girault S, Chassaing G, Blais JC, Brunot A & Bolbach G (1996) Coupling of MALDI-TOF mass analysis to
18 14 the separation of biotinylated peptides by magnetic streptavidin beads. *Anal Chem* **68**: 2122-2126.
- 19 15 Graham R, Graham C & McMullan G (2007) Microbial proteomics: a mass spectrometry primer for
20 16 biologists. *Microbial cell factories* **6**: 26.
- 22 17 Haag AM, Taylor SN, Johnston KH & Cole RB (1998) Rapid identification and speciation of
23 18 *Haemophilus* bacteria by matrix-assisted laser desorption/ionization time-of-flight mass
24 19 spectrometry. *J Mass Spectrom* **33**: 750-756.
- 25 20 Hathout Y, Ho YP, Ryzhov V, Demirev P & Fenselau C (2000) Kurstakins: a new class of lipopeptides
26 21 isolated from *Bacillus thuringiensis*. *J Nat Prod* **63**: 1492-1496.
- 27 22 Hazen TH, Martinez RJ, Chen Y, *et al.* (2009) Rapid identification of *Vibrio parahaemolyticus* by
28 23 whole-cell matrix-assisted laser desorption ionization-time of flight mass spectrometry. *Appl Environ*
29 24 *Microbiol* **75**: 6745-6756.
- 31 25 Heller DN, Cotter RJ, Fenselau C & Uy OM (1987) Profiling of bacteria by fast atom bombardment
32 26 mass spectrometry. *Anal Chem* **59**: 2806-2809.
- 33 27 Heller DN, Murphy CM, Cotter RJ, Fenselau C & Uy OM (1988) Constant neutral loss scanning for the
34 28 characterization of bacterial phospholipids desorbed by fast atom bombardment. *Anal Chem* **60**:
35 29 2787-2791.
- 37 30 Hettick JM, Kashon ML, Simpson JP, Siegel PD, Mazurek GH & Weissman DN (2004) Proteomic
38 31 profiling of intact mycobacteria by matrix-assisted laser desorption/ionization time-of-flight mass
39 32 spectrometry. *Anal Chem* **76**: 5769-5776.
- 40 33 Hettick JM, Green BJ, Buskirk AD, *et al.* (2008) Discrimination of *Aspergillus* isolates at the species
41 34 and strain level by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry
42 35 fingerprinting. *Anal Biochem* **380**: 276-281.
- 44 36 Hettick JM, Green BJ, Buskirk AD, *et al.* (2008) Discrimination of *Penicillium* isolates by matrix-
45 37 assisted laser desorption/ionization time-of-flight mass spectrometry fingerprinting. *Rapid Commun*
46 38 *Mass Spectrom* **22**: 2555-2560.
- 47 39 Ho YP & Fenselau C (1998) Applications of 1.06-micron IR laser desorption on a Fourier transform
48 40 mass spectrometer. *Anal Chem* **70**: 4890-4895.
- 49 41 Holland RD, Wilkes JG, Rafii F, Sutherland JB, Persons CC, Voorhees KJ & Lay JO, Jr. (1996) Rapid
50 42 identification of intact whole bacteria based on spectral patterns using matrix-assisted laser
51 43 desorption/ionization with time-of-flight mass spectrometry. *Rapid Commun Mass Spectrom* **10**:
52 44 1227-1232.
- 54 45 Holland RD, Duffy CR, Rafii F, *et al.* (1999) Identification of bacterial proteins observed in MALDI TOF
55 46 mass spectra from whole cells. *Anal Chem* **71**: 3226-3230.
- 56 47 Hsieh SY, Tseng CL, Lee YS, Kuo AJ, Sun CF, Lin YH & Chen JK (2008) Highly efficient classification and
57 48 identification of human pathogenic bacteria by MALDI-TOF MS. *Mol Cell Proteomics* **7**: 448-456.
- 59 49 Jackson KA, Edwards-Jones V, Sutton CW & Fox AJ (2005) Optimisation of intact cell MALDI method
50 50 for fingerprinting of methicillin-resistant *Staphylococcus aureus*. *J Microbiol Methods* **62**: 273-284.
- 51 51 Jonsson AP (2001) Mass spectrometry for protein and peptide characterisation. *Cellular and*
52 52 *molecular life sciences : CMLS* **58**: 868-884.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1 Karger A, Ziller M, Bettin B, Mintel B, Schares S & Geue L (2011) Determination of serotypes of Shiga toxin-producing *Escherichia coli* isolates by intact cell matrix-assisted laser desorption ionization-time of flight mass spectrometry. *Appl Environ Microbiol* **77**: 896-905.
- 2 Kawamura Y, Hou XG, Sultana F, Miura H & Ezaki T (1995) Determination of 16S rRNA sequences of *Streptococcus mitis* and *Streptococcus gordonii* and phylogenetic relationships among members of the genus *Streptococcus*. *Int J Syst Bacteriol* **45**: 406-408.
- 3 Kemptner J, Marchetti-Deschmann M, Mach R, Druzhinina IS, Kubicek CP & Allmaier G (2009) Evaluation of matrix-assisted laser desorption/ionization (MALDI) preparation techniques for surface characterization of intact *Fusarium* spores by MALDI linear time-of-flight mass spectrometry. *Rapid Commun Mass Spectrom* **23**: 877-884.
- 4 Kollef MH (2000) Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* **31 Suppl 4**: S131-138.
- 5 Krause E, Wenschuh H & Jungblut PR (1999) The dominance of arginine-containing peptides in MALDI-derived tryptic mass fingerprints of proteins. *Anal Chem* **71**: 4160-4165.
- 6 Krishnamurthy T & Ross PL (1996) Rapid identification of bacteria by direct matrix-assisted laser desorption/ionization mass spectrometric analysis of whole cells. *Rapid Commun Mass Spectrom* **10**: 1992-1996.
- 7 La Scola B & Raoult D (2009) Direct identification of bacteria in positive blood culture bottles by matrix-assisted laser desorption ionisation time-of-flight mass spectrometry. *PLoS One* **4**: e8041.
- 8 Lay JO, Jr. (2001) MALDI-TOF mass spectrometry of bacteria. *Mass Spectrom Rev* **20**: 172-194.
- 9 Lefmann M, Honisch C, Bocker S, *et al.* (2004) Novel mass spectrometry-based tool for genotypic identification of mycobacteria. *Journal of clinical microbiology* **42**: 339-346.
- 10 Leibovici L, Shraga I, Drucker M, Konigsberger H, Samra Z & Pitlik SD (1998) The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection. *Journal of internal medicine* **244**: 379-386.
- 11 Li TY, Liu BH & Chen YC (2000) Characterization of *Aspergillus* spores by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. *Rapid Commun Mass Spectrom* **14**: 2393-2400.
- 12 Liang X, Zheng K, Qian MG & Lubman DM (1996) Determination of bacterial protein profiles by matrix-assisted laser desorption/ionization mass spectrometry with high-performance liquid chromatography. *Rapid Commun Mass Spectrom* **10**: 1219-1226.
- 13 Liu H, Du Z, Wang J & Yang R (2007) Universal sample preparation method for characterization of bacteria by matrix-assisted laser desorption ionization-time of flight mass spectrometry. *Appl Environ Microbiol* **73**: 1899-1907.
- 14 Lotz A, Ferroni A, Beretti JL, *et al.* (2010) Rapid identification of mycobacterial whole cells in solid and liquid culture media by matrix-assisted laser desorption ionization-time of flight mass spectrometry. *J Clin Microbiol* **48**: 4481-4486.
- 15 Madonna AJ, Basile F, Ferrer I, Meetani MA, Rees JC & Voorhees KJ (2000) On-probe sample pretreatment for the detection of proteins above 15 KDa from whole cell bacteria by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. *Rapid Commun Mass Spectrom* **14**: 2220-2229.
- 16 Marinach-Patrice C, Lethuillier A, Marly A, *et al.* (2009) Use of mass spectrometry to identify clinical *Fusarium* isolates. *Clin Microbiol Infect* **15**: 634-642.
- 17 Marinach-Patrice C, Fekkar A, Atanasova R, *et al.* (2010) Rapid species diagnosis for invasive candidiasis using mass spectrometry. *PLoS One* **5**: e8862.
- 18 Marklein G, Josten M, Klanke U, *et al.* (2009) Matrix-assisted laser desorption ionization-time of flight mass spectrometry for fast and reliable identification of clinical yeast isolates. *J Clin Microbiol* **47**: 2912-2917.
- 19 Meetani MA, Shin YS, Zhang S, Mayer R & Basile F (2007) Desorption electrospray ionization mass spectrometry of intact bacteria. *J Mass Spectrom* **42**: 1186-1193.

- 1 Mellmann A, Cloud J, Maier T, *et al.* (2008) Evaluation of matrix-assisted laser desorption ionization-time-of-flight mass spectrometry in comparison to 16S rRNA gene sequencing for species identification of nonfermenting bacteria. *J Clin Microbiol* **46**: 1946-1954.
- 2 Mellmann A, Bimet F, Bizet C, *et al.* (2009) High interlaboratory reproducibility of matrix-assisted laser desorption ionization-time of flight mass spectrometry-based species identification of nonfermenting bacteria. *J Clin Microbiol* **47**: 3732-3734.
- 3 Montero CI, Shea YR, Jones PA, Harrington SM, Tooke NE, Witebsky FG & Murray PR (2008) Evaluation of Pyrosequencing technology for the identification of clinically relevant non-dematiaceous yeasts and related species. *Eur J Clin Microbiol Infect Dis* **27**: 821-830.
- 4 Moussaoui W, Jaulhac B, Hoffmann AM, Ludes B, Kostrzewa M, Riegel P & Prevost G (2010) Matrix-assisted laser desorption ionization time-of-flight mass spectrometry identifies 90% of bacteria directly from blood culture vials. *Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases* **16**: 1631-1638.
- 5 Munson EL, Diekema DJ, Beekmann SE, Chapin KC & Doern GV (2003) Detection and treatment of bloodstream infection: laboratory reporting and antimicrobial management. *Journal of clinical microbiology* **41**: 495-497.
- 6 Murray PR (2010) Matrix-assisted laser desorption ionization time-of-flight mass spectrometry: usefulness for taxonomy and epidemiology. *Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases* **16**: 1626-1630.
- 7 Nagy E, Maier T, Urban E, Terhes G & Kostrzewa M (2009) Species identification of clinical isolates of *Bacteroides* by matrix-assisted laser-desorption/ionization time-of-flight mass spectrometry. *Clin Microbiol Infect* **15**: 796-802.
- 8 Nyvang Hartmeyer G, Kvistholm Jensen A, Bocher S, *et al.* (2010) Mass spectrometry: pneumococcal meningitis verified and *Brucella* species identified in less than half an hour. *Scandinavian journal of infectious diseases* **42**: 716-718.
- 9 Pignone M, Greth KM, Cooper J, Emerson D & Tang J (2006) Identification of mycobacteria by matrix-assisted laser desorption ionization-time-of-flight mass spectrometry. *Journal of clinical microbiology* **44**: 1963-1970.
- 10 Pignone M, Greth KM, Cooper J, Emerson D & Tang J (2006) Identification of mycobacteria by matrix-assisted laser desorption ionization-time-of-flight mass spectrometry. *J Clin Microbiol* **44**: 1963-1970.
- 11 Pineda FJ, Lin JS, Fenselau C & Demirev PA (2000) Testing the significance of microorganism identification by mass spectrometry and proteome database search. *Anal Chem* **72**: 3739-3744.
- 12 Platt JA, Uy OM, Heller DN, Cotter RJ & Fenselau C (1988) Computer-based linear regression analysis of desorption mass spectra of microorganisms. *Anal Chem* **60**: 1415-1419.
- 13 Pribil P & Fenselau C (2005) Characterization of Enterobacteria using MALDI-TOF mass spectrometry. *Anal Chem* **77**: 6092-6095.
- 14 Prod'hom G, Bizzini A, Durussel C, Bille J & Greub G (2010) Matrix-assisted laser desorption ionization-time of flight mass spectrometry for direct bacterial identification from positive blood culture pellets. *Journal of clinical microbiology* **48**: 1481-1483.
- 15 Romero-Gomez MP & Mingorance J (2011) The effect of the blood culture bottle type in the rate of direct identification from positive cultures by matrix-assisted laser desorption/ionisation time-of-flight (MALDI-TOF) mass spectrometry. *The Journal of infection* **62**: 251-253.
- 16 Ruelle V, El Moualij B, Zorzi W, Ledent P & Pauw ED (2004) Rapid identification of environmental bacterial strains by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. *Rapid Commun Mass Spectrom* **18**: 2013-2019.
- 17 Rupf S, Breitung K, Schellenberger W, Merte K, Kneist S & Eschrich K (2005) Differentiation of mutans streptococci by intact cell matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. *Oral Microbiol Immunol* **20**: 267-273.
- 18 Ryzhov V & Fenselau C (2001) Characterization of the protein subset desorbed by MALDI from whole bacterial cells. *Anal Chem* **73**: 746-750.

- 1
2
3
4 1 Saenz AJ, Petersen CE, Valentine NB, Gantt SL, Jarman KH, Kingsley MT & Wahl KL (1999)
5 2 Reproducibility of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for
6 3 replicate bacterial culture analysis. *Rapid Commun Mass Spectrom* **13**: 1580-1585.
7 4 Schabereiter-Gurtner C, Selitsch B, Rotter ML, Hirschl AM & Willinger B (2007) Development of novel
8 5 real-time PCR assays for detection and differentiation of eleven medically important *Aspergillus* and
9 6 *Candida* species in clinical specimens. *J Clin Microbiol* **45**: 906-914.
10 7 Seng P, Drancourt M, Gouriet F, La Scola B, Fournier PE, Rolain JM & Raoult D (2009) Ongoing
11 8 revolution in bacteriology: routine identification of bacteria by matrix-assisted laser desorption
12 9 ionization time-of-flight mass spectrometry. *Clin Infect Dis* **49**: 543-551.
13 10 Seyfarth F, Ziemer M, Sayer HG, *et al.* (2008) The use of ITS DNA sequence analysis and MALDI-TOF
14 11 mass spectrometry in diagnosing an infection with *Fusarium proliferatum*. *Exp Dermatol* **17**: 965-971.
15 12 Shah HN & Collins MD (1980) Fatty acid and isoprenoid quinone composition in the classification of
16 13 *Bacteroides melaninogenicus* and related taxa. *J Appl Bacteriol* **48**: 75-87.
17 14 She YM, Haber S, Seifers DL, *et al.* (2001) Determination of the complete amino acid sequence for the
18 15 coat protein of brome mosaic virus by time-of-flight mass spectrometry. Evidence for mutations
19 16 associated with change of propagation host. *J Biol Chem* **276**: 20039-20047.
20 17 Siegrist TJ, Anderson PD, Huen WH, Kleinheinz GT, McDermott CM & Sandrin TR (2007)
21 18 Discrimination and characterization of environmental strains of *Escherichia coli* by matrix-assisted
22 19 laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS). *J Microbiol Methods*
23 20 **68**: 554-562.
24 21 Spanu T, De Carolis E, Fiori B, Sanguinetti M, D'Inzeo T, Fadda G & Posteraro B (2011) Evaluation of
25 22 matrix-assisted laser desorption ionization-time-of-flight mass spectrometry in comparison to *rpoB*
26 23 gene sequencing for species identification of bloodstream infection staphylococcal isolates. *Clinical*
27 24 *microbiology and infection : the official publication of the European Society of Clinical Microbiology*
28 25 *and Infectious Diseases* **17**: 44-49.
29 26 Speers DJ, Olma TR & Gilbert GL (1998) Evaluation of four methods for rapid identification of
30 27 *Staphylococcus aureus* from blood cultures. *J Clin Microbiol* **36**: 1032-1034.
31 28 Stevenson LG, Drake SK & Murray PR (2010) Rapid identification of bacteria in positive blood culture
32 29 broths by matrix-assisted laser desorption ionization-time of flight mass spectrometry. *J Clin*
33 30 *Microbiol* **48**: 444-447.
34 31 Stevenson LG, Drake SK, Shea YR, Zelazny AM & Murray PR (2010) Evaluation of matrix-assisted laser
35 32 desorption ionization-time of flight mass spectrometry for identification of clinically important yeast
36 33 species. *J Clin Microbiol* **48**: 3482-3486.
37 34 Suh MJ & Limbach PA (2004) Investigation of methods suitable for the matrix-assisted laser
38 35 desorption/ionization mass spectrometric analysis of proteins from ribonucleoprotein complexes. *Eur*
39 36 *J Mass Spectrom (Chichester, Eng)* **10**: 89-99.
40 37 Sun L, Teramoto K, Sato H, Torimura M, Tao H & Shintani T (2006) Characterization of ribosomal
41 38 proteins as biomarkers for matrix-assisted laser desorption/ionization mass spectral identification of
42 39 *Lactobacillus plantarum*. *Rapid Commun Mass Spectrom* **20**: 3789-3798.
43 40 Szabados F, Michels M, Kaase M & Gatermann S (2011) The sensitivity of direct identification from
44 41 positive BacT/ALERT (bioMerieux) blood culture bottles by matrix-assisted laser desorption ionization
45 42 time-of-flight mass spectrometry is low. *Clinical microbiology and infection : the official publication of*
46 43 *the European Society of Clinical Microbiology and Infectious Diseases* **17**: 192-195.
47 44 Tanaka K & Fenn JB (2002) Nobel Laureates in chemistry. <http://www.nobelprize.org>. ed.^eds.),
48 45 p.^pp.
49 46 Teramoto K, Sato H, Sun L, *et al.* (2007) Phylogenetic classification of *Pseudomonas putida* strains by
50 47 MALDI-MS using ribosomal subunit proteins as biomarkers. *Anal Chem* **79**: 8712-8719.
51 48 Vaidyanathan S, Winder CL, Wade SC, Kell DB & Goodacre R (2002) Sample preparation in matrix-
52 49 assisted laser desorption/ionization mass spectrometry of whole bacterial cells and the detection of
53 50 high mass (>20 kDa) proteins. *Rapid Commun Mass Spectrom* **16**: 1276-1286.

- 1
2
3 1 Valentine N, Wunschel S, Wunschel D, Petersen C & Wahl K (2005) Effect of culture conditions on
4 2 microorganism identification by matrix-assisted laser desorption ionization mass spectrometry. *Appl*
5 3 *Environ Microbiol* **71**: 58-64.
6 4 Valentine NB, Wahl JH, Kingsley MT & Wahl KL (2002) Direct surface analysis of fungal species by
7 5 matrix-assisted laser desorption/ionization mass spectrometry. *Rapid Commun Mass Spectrom* **16**:
8 6 1352-1357.
9 7 van Veen SQ, Claas EC & Kuijper EJ (2010) High-throughput identification of bacteria and yeast by
10 8 matrix-assisted laser desorption ionization-time of flight mass spectrometry in conventional medical
11 9 microbiology laboratories. *J Clin Microbiol* **48**: 900-907.
12 10 Vargha M, Takats Z, Konopka A & Nakatsu CH (2006) Optimization of MALDI-TOF MS for strain level
13 11 differentiation of *Arthrobacter* isolates. *J Microbiol Methods* **66**: 399-409.
14 12 von Eiff C, Peters G & Heilmann C (2002) Pathogenesis of infections due to coagulase-negative
15 13 staphylococci. *Lancet Infect Dis* **2**: 677-685.
16 14 Walker J, Fox AJ, Edwards-Jones V & Gordon DB (2002) Intact cell mass spectrometry (ICMS) used to
17 15 type methicillin-resistant *Staphylococcus aureus*: media effects and inter-laboratory reproducibility. *J*
18 16 *Microbiol Methods* **48**: 117-126.
19 17 Wang ZP, Russon L, Li L, Roser DC & Long SR (1998) Investigation of spectral reproducibility in direct
20 18 analysis of bacteria proteins by matrix-assisted laser desorption/ionization time-of-flight mass
21 19 spectrometry. *Rapid Commun Mass Spectrom* **12**: 456-464.
22 20 Welham KJ, Domin MA, Scannell DE, Cohen E & Ashton DS (1998) The characterization of micro-
23 21 organisms by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. *Rapid*
24 22 *Commun Mass Spectrom* **12**: 176-180.
25 23 Welham KJ, Domin MA, Johnson K, Jones L & Ashton DS (2000) Characterization of fungal spores by
26 24 laser desorption/ionization time-of-flight mass spectrometry. *Rapid Commun Mass Spectrom* **14**:
27 25 307-310.
28 26 Williams TL, Andrzejewski D, Lay JO & Musser SM (2003) Experimental factors affecting the quality
29 27 and reproducibility of MALDI TOF mass spectra obtained from whole bacteria cells. *J Am Soc Mass*
30 28 *Spectrom* **14**: 342-351.
31 29 Wolters M, Rohde H, Maier T, *et al.* (2011) MALDI-TOF MS fingerprinting allows for discrimination of
32 30 major methicillin-resistant *Staphylococcus aureus* lineages. *International journal of medical*
33 31 *microbiology : IJMM* **301**: 64-68.
34 32 Wunschel SC, Jarman KH, Petersen CE, *et al.* (2005) Bacterial analysis by MALDI-TOF mass
35 33 spectrometry: an inter-laboratory comparison. *J Am Soc Mass Spectrom* **16**: 456-462.
36 34 Wybo I, De Bel A, Soetens O, Echahidi F, Vandoorslaer K, Van Cauwenbergh M & Pierard D (2011)
37 35 Differentiation of *cfiA*-Negative and *cfiA*-Positive *Bacteroides fragilis* Isolates by Matrix-Assisted Laser
38 36 Desorption Ionization-Time of Flight Mass Spectrometry. *Journal of clinical microbiology* **49**: 1961-
39 37 1964.
40
41
42
43
44
45
46
47 38
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
471
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
471
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

References	N	Description	Genus level (%)	Species level (%)	Mis-identification (%)	No ID (%)	Comments
(van Veen, <i>et al.</i> , 2010)	327	Total	95.1	85.6	3	3.9	<ul style="list-style-type: none"> • Retrospective intra-laboratory study • Misidentification: associated with absence or mislabeling of reference spectra in the database
	89	<i>Enterobacteriaceae</i>	100	96.6	3.4	0	
	55	Non-fermentative GN	81.8	74.5	5.4	14.5	
	87	GP cocci	97.7	80.5	1.1	2.3	
	77	Miscellaneous bacteria (HACCEK)	94.8	84.4	3.9	1.3	
	19	Yeasts	100	94.7	0	0	
(van Veen, <i>et al.</i> , 2010)	980	Total	98.8	92	1.7	1.1	<ul style="list-style-type: none"> • Prospective intra-laboratory study • Misidentification: associated with absence or mislabeling of reference spectra in the database • Viridans streptococci and pneumococci characterized by many misidentifications. • Weakness of the study: lack of sufficient anaerobic bacteria and GP aerobic rods included in the tested samples.
	311	<i>Enterobacteriaceae</i>	100	97.7	0.3	0	
	88	Non-fermentative GN	94.3	92	1.1	4.6	
	261	GP cocci in cluster	100	94.3	0.4	0	
	165	GP cocci in chains	98.8	84.8	7.3	1.2	
		Enterococci	100	98.4	0	0	
		Hemolytic streptococci	100	100	0	0	
		<i>Streptococcus milleri</i> group	100	77.8	0	0	
		Pneumococci	100	86.4	0	0	
		Viridans streptococci	90.5	9.5	57.1	9.5	
	94	Miscellaneous bacteria (HACCEK)	96.8	84	0	3.2	
	61	Yeasts	96.7	85.2	3.3	3.2	
(Seng, <i>et al.</i> , 2009)	1660	Total	95.4	84.1	1.7	2.8	<ul style="list-style-type: none"> • Prospective intra-laboratory study • Lack of identification mainly for non-<i>Clostridium</i> anaerobes due to an absence of reference spectra in the database
	ND	GP			0.8	2	
	ND	GN			0.9	0.7	
(Cherkaoui, <i>et al.</i> , 2010)	720	Total	100	94 ^a / 89 ^b	0.9 ^a / 0.5 ^b		<ul style="list-style-type: none"> • Comparative intra-laboratory study of two commercial MALDI-TOF MS devices (Bruker and Shimatzu) • Bruker system ^a • Shimatzu ^b • Poor yield for streptococcal species and for GN anaerobes (less than 50% correct identification).
	416	<i>Enterobacteriaceae</i>		99.8 ^a / 95.9 ^b	0 ^a / 0 ^b		
	80	Aerobic GN		97.5 ^a / 96.3 ^b	1.25 ^a / 0 ^b		
	111	Staphylococci		98.2 ^a / 96.4 ^b	0.9 ^a / 0.9 ^b		
	87	Aerobic GP		73.6 ^a / 55.2 ^b	3.4 ^a / 2.3 ^b		
	6	Anaerobic GN		17 ^a / 0 ^b	0 ^a / 0 ^b		
	7	Anaerobic GP		57 ^a / 43 ^b	25 ^a / 0 ^b		

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

(Mellmann, <i>et al.</i> , 2009)	480 60 60 60 60 60 60 60	Total Laboratory A Laboratory B Laboratory C Laboratory D Laboratory E Laboratory F Laboratory G Laboratory H		98.7 100 96.67 100 93.33 100 100 100	1.04 0 1.7 0 6.66 0 0 0	0.2 0 1.7 0 0 0 0 0	<ul style="list-style-type: none"> • Interlaboratory study • 60 non-fermenting bacteria were shipped to 8 different laboratories with access to Bruker platforms. • No significant difference between direct application and preprocessed samples • Misidentification: sample interchange (4) and skin contamination (1)
(Bizzini, <i>et al.</i> , 2010)	1371 1371 525 525 729 729 24 24	Total direct application Total protein extraction GP direct application GP protein extraction GN direct application GN protein extraction Yeasts direct application Yeasts protein extraction	95.4 99.6 97 100	70.3 92.6 73.7 98.85 71.6 92.2 4.1 100	4.2 0.95 7 0	4.6 0.4 3 0	<ul style="list-style-type: none"> • Intra-laboratory study • Protein extraction increases the total yield of valid results by 25% compared to direct application. • Misidentification: inaccurate taxonomic assignment, change in the taxonomy, limit of resolution of the method.
(Marklein, <i>et al.</i> , 2009)	267 267	Total before complementation of database Total after complementation of the database		92.5 100		7.5 0	<ul style="list-style-type: none"> • Intra-laboratory study of clinical yeast isolates (<i>Candida</i> (n=250), <i>Cryptococcus</i>, <i>Saccharomyces</i>, <i>Trichosporon</i>, <i>Geotrichum</i>, <i>Pichia</i> and <i>Blastoschizomyces</i> spp.) • All isolates identified upon complementation of the database with appropriate reference strains. • All samples were preprocessed with a protein extraction step before deposition
(Bader, <i>et al.</i> , 2010)	1192 1175 ^a / 1152 ^b	Total Challenged against respective database		97.6 ^a /96.1 ^b 99 ^a / 99.4 ^b	0.7 ^a / 0.2 ^b 0.5 ^a / 0 ^b	1.7 ^a / 3.7 ^b 0.5 ^a / 0.6 ^b	<ul style="list-style-type: none"> • Comparative intra-laboratory study of two commercial MALDI-TOF MS devices (Bruker and Shimatzu) on clinical yeast isolates. • Bruker system ^a • Shimatzu ^b • Better yield observed when the performance is only tested on species present in respective databases • All sample were preprocessed with a protein extraction step before deposition

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

1 N, sample number. Genus and species level (%), percent of identification at the genus and species level respectively. Misidentification (%), percent of
2
3
4 2 misidentified samples. No ID (%), percent of samples not identified. GP, Gram-positive. GN, Gram-negative.
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

1

2 **Table 3.** Performance of MALDI-TOF identification obtained from positive blood culture.

Reference	Sample (n)	Blood culture system	Concordant identification to species level	Concordant identification to genus level	Identification difficulty	Comments
(Prod'hom, <i>et al.</i> , 2010)	126	positive blood culture (Bactec)	78%, GN: 89%, GP: 72%	79%, GN: 89%, GP: 73%	<i>Streptococcus mitis</i> group, <i>Staphylococcus</i> spp.	Use of ammonium chloride to lyse erythrocyte. The presence of a capsule explain partially the low identification rate of <i>S. pneumoniae</i> , <i>H. influenzae</i> , <i>K. pneumoniae</i>
(La Scola & Raoult, 2009)	599	positive blood culture (Bactec)	66% GN : 91% GP : 49%	66%	<i>Streptococcus</i> spp., polymicrobial samples	During the study, modification of the extraction protocol to improve <i>Staphylococci</i> identification (38% - >75%).
(Stevenson, <i>et al.</i> , 2010)	212	positive blood culture (179), spiked bottles (33) (Bactec)	80%	80%	<i>Streptococcus mitis</i> group, <i>Propionobacterium acnes</i>	Use of a separator device for blood cells removal.
(Ferroni, <i>et al.</i> , 2010)	685	positive blood culture (388), spiked bottles (312)	89%	98%	<i>Streptococcus pneumoniae</i> , <i>Streptococcus mitis</i> group, polymicrobial samples	Use of saponin to lyse erythrocyte.
(Christner, <i>et al.</i> , 2010)	277	positive blood culture (Bactec)	94%	95%	Cocci GP	Mismatch mostly resulted from insufficient bacterial quantity and occurred preferentially with GP bacteria

(Ferreira, <i>et al.</i> , 2010)	300	positive blood culture (Bactec)	43%, GN: 83%, GP: 32%	72%, GN: 97%, GP: 66%	<i>Streptococcus mutans</i> , <i>Staphylococcus</i> spp., <i>Staphylococcus aureus</i>	No mixed culture
(Ferreira, <i>et al.</i> , 2010)	68	positive blood culture (Bactec)	76% ICM 47% PEM 76%	96% ICM 51% PEM 93%	<i>Staphylococcus</i> spp.	PEM improve the identification compared to ICM
(Marinach-Patrice, <i>et al.</i> , 2010)	48	spiked bottles with <i>Candida</i> (Bactec)	100%	100%		Use of SDS as detergent to lyse erythrocytes. Application of a new algorithm's concept since residual blood proteins and <i>Candida</i> share many masses in common.
(Szabados, <i>et al.</i> , 2011)	268	positive blood culture (BacT/ALERT) (non charcoal containing bottles)	31%	ND	Polymicrobial samples	In a preliminary study, a lower rate of identification with charcoal-containing bottle was observed (8%).
(Romero-Gomez & Mingorance, 2011)	129	positive blood culture Bactec (42) Versatrek (35) BacT/ALERT (52)	68% 76% (Bactec) 69% (Versatrek) 62% (BacT/Alert)	ND	Significant lower performance for GP bacteria	

Adapted from Carbonelle 2010, (Carbonelle, *et al.*, 2010), GN: Gram-negative bacteria, GP: Gram-positive bacteria, ICM: intact cell method, PEM: protein extraction method, SDS: Sodium Dodecyl Sulfate, ND: not determined.

1 **Figure legends**

2 **Figure 1.** Technical description of MALDI-TOF MS. The sample is mixed with a matrix on a
3 conductive metal plate. After crystallisation of the matrix and microbial material, the metal
4 plate is introduced in the mass spectrometer and is bombarded with brief laser pulses. The
5 desorbed and ionized molecules are accelerated through an electrostatic field and ejected
6 through a metal flight tube subjected to vacuum until they reach a detector, with smaller ions
7 travelling faster than larger ions. Thus, bioanalytes separated according to their time of flight
8 (TOF) create a mass spectrum that is composed by mass to charge ratio (m/z) peaks with
9 varying intensities. A spectrum is thus a microbial signature that is compared to a database for
10 the identification at the species or genus level.

11 **Figure 2.** Intra-laboratory reproducibility tested by measuring the number of conserved peaks
12 in two experimental settings. In the first setting, ethanol/formic acid extraction was applied on
13 *E. coli* ATCC 25922 (A) or *S. aureus* ATCC 25923 (B) and 10 replicates of one extraction
14 were spotted onto the MALDI-TOF microplate (1µl, about 10⁶ bacteria/µl). In the second
15 setting, 10 independent extractions were done and one replicate of each extraction was spotted
16 onto the MALDI-TOF microplate. After smoothing and baseline subtraction, the 100 highest
17 peaks from each spot were selected and the number of time a given peak is present out of 10
18 times was determined for each peak in the two different settings for *E. coli* and *S. aureus*.

19 **Figure 3.** The amount of material is a critical factor for accurate microbial identification by
20 MALDI-TOF MS. (A) Spectral fingerprints obtained from various quantities (10⁶ to 10³) of *E.*
21 *coli* ATCC 25922 grown on blood agar plates. The inoculums were prepared from a sample
22 with a turbidity of 4.0 McFarland that was diluted to obtain the approximate quantity used for
23 direct microplate deposition (10⁶ to 10³ bacteria per spot). Protein extraction was performed
24 by directly mixing the samples with formic acid on microplate. The results show that the
25 quality of the spectrum and thus the performance of identification are largely dependent on

1 the sample amount spotted on the microplate. (B) Growth of *Staphylococcus epidermidis* on
2 blood agar plates at 35°C in 5% CO₂ atmosphere after an incubation of 2, 4, 6, 8 hours,
3 respectively. Usually, at least 6 hours incubation are required to get sufficient amount of
4 material to obtain an efficient MALDI-TOF MS identification (C) Cumulative percentage of
5 MALDI-TOF identification obtained from Gram-negative (*Escherichia coli* (13),
6 *Pseudomonas putida* (2), *Klebsiella pneumoniae* (2), *Enterobacter cloacae* (1)) and Gram-
7 positive (*Staphylococcus epidermidis* (13), *Staphylococcus aureus* (9), *Streptococcus*
8 *pyogenes* (4), *Streptococcus pneumoniae* (1), *Staphylococcus hominis* (1)) bacteria after
9 short-time plating on agar during 2, 4, 6, 8 hours, respectively. The number of samples for
10 each bacterial species analysed is indicated in brackets.

11 **Figure 4.** Importance of the organization of a working day to optimize time to results. Each
12 line represents a MALDI-TOF run, with the waiting time for equipment availability, the time
13 required to prepare the target layout and the time of the MALDI-TOF running process. In this
14 example of a working day, eight MALDI-TOF target plates have been used to analyse
15 multiple clinical samples (ICU, S: intensive care unit and surgery (1 run); IM, P: internal
16 medicine, pediatry and others (1 target plate); BC: blood cultures (4 runs); U: urine (2 runs)).
17 Urgent samples such as blood cultures are directly processed while colonies identification
18 from agar cultures are processed by batch. The processing of the samples is organized to
19 guarantee the optimal use of the MALDI-TOF device during the working day.

20 **Figure 5.** *E. coli* identification yield in urine samples. Five ml of urine samples positive by
21 microscopy were centrifuged to concentrate and collect the bacteria. The pellet was
22 resuspended in 200µl water and subjected to protein extraction with ethanol and formic acid
23 prior deposition on the microplate. The graph shows the identification yield according to the
24 bacterial load per ml.

1
2
3 1 **Figure 6.** Importance of the maintenance and quality controls of the MALDI-TOF device
4
5 2 demonstrated by a follow-up of the temporal reproducibility. (A) Spectral fingerprint of *S.*
6
7 3 *aureus* quality controls during a 10 weeks control period. (B) Percentage of conserved peaks
8
9 4 during a 10 weeks control period. *E. coli* and *S. aureus* quality controls fingerprints were
10
11 5 compared to a set of conserved peaks (81 and 80 respectively). The poor performance
12
13 6 observed during week 1 to 3 was likely caused by a problem of inadequate sample deposition
14
15 7 on the MALDI-TOF MS microplates.

16
17
18 8 **Figure 7.** Quality control for MALDI-TOF mass spectrometry. (A) Presence of residual
19
20 9 materials on some wells (especially C4, E3 and E4, indicated by white arrows) of a MALDI-
21
22 10 TOF micropalte after a routine wash, highlighting the importance of careful wash after each
23
24 11 usage; (B) mass spectra obtained with the Bruker BST control, that consists in lyophilized *E.*
25
26 12 *coli* spiked with RNase A (black arrow at a m/z of 13683) and myoglobin (white arrow at a
27
28 13 m/z of 16952); in the lower part of the panel, the list of the eight proteins that should be
29
30 14 present to validate the run and their expected and observed m/z values.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 **Supplementary materials.**

2 3 **Box S1.**

4 **Hardwares and Softwares**

5 To date, mainly two MALDI-TOF MS instruments, commercialized by Bruker Daltonics
6 (Bruker Daltonik GmbH, Bremen, Germany) and Shimadzu (Shimadzu Corporation, Kyoto,
7 Japan), are available for routine microbiology. The two companies have different data
8 analysis solutions to process raw MALDI-TOF spectra and to compare this data with spectra
9 of reference libraries. The Bruker instrument provides its own software package, the MALDI
10 Biotyper (Bruker Daltonik GmbH, Bremen, Germany), which includes software and database.
11 The Shimadzu instrument provides the Shimadzu Launchpad software and uses the
12 SARAMIS database (Spectral Archiving and Microbial Identification System, AnagnosTec
13 GmbH, Germany). Both software packages allow processing of raw data (baseline
14 subtraction, smoothing, and normalization) and comparison of the processed data to a built-
15 in reference library. The reliability of this technology largely depends on the reference
16 database and the algorithm used for spectral comparison.

17 The BioTyper reference library currently contains reference spectra for more than 3200
18 reference strains (Nagy, *et al.*, 2009) and reference spectra for newly investigated bacteria can
19 be added to the reference library (Barbuddhe, *et al.*, 2008, Mellmann, *et al.*, 2008). The
20 library spectra are generated by multiple measurements (average of 20 measured spectra) of
21 known bacterial isolates under slightly different conditions to extract specific peak
22 information. The software automatically generates peak lists from the whole set of spectra and
23 extracts typical peaks which are present in a certain number of spectra from one species.

1
2
3 1 The SARAMIS database contains over 62,500 single fingerprint spectra of different isolates
4
5 2 representing more than 1,160 species, 233 genera and 2,700 super-spectra. Indeed, the
6
7 3 SARAMIS database contains two types of spectra: super-spectra and reference spectra. Super-
8
9 4 spectra are consensus spectra of multiple mass spectra of reference strains of individual
10
11 5 serotypes, species or genera, respectively. A super-spectrum can thus be considered as a
12
13 6 reference peak signature of multiple isolates of a species that include a subset of characteristic
14
15 7 and reproducible markers (typically 15). The concept of super-spectra has been developed to
16
17 8 cope with the natural diversity found in all microbial species which can results in variation of
18
19 9 the peaks pattern. The SARAMIS database contains nowadays about 2,700 super-spectra
20
21 10 corresponding to 900 different microbial species. Since by definition super-spectra represent
22
23 11 the most typical isolates of a species, some less frequent isolates of a given species will not be
24
25 12 detected in routine analysis and are then processed using a second-line identification process
26
27 13 through a direct comparison to all reference spectra present in the database.
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
1 Table S1. Summarized characteristics of several types of mass analysers.

Mass analyser	Advantages	Disadvantages
Time of flight (TOF)	<ul style="list-style-type: none"> • Unlimited mass range (m/z) • Good mass accuracy and resolution • Simplest mass analyser. Compact and easy to manipulate instrument. • Easily adapted to MALDI. • Low cost. 	<ul style="list-style-type: none"> • Less adapted to ESI than MALDI.
Fourier transform ion cyclotron resonance (FTICR)	<ul style="list-style-type: none"> • High mass range, up to 10'000 m/z • Excellent mass accuracy and resolution. • Easily adapted to MALDI and ESI • Well suited to analyse complex mixtures 	<ul style="list-style-type: none"> • Expensive, require superconducting magnet.
Quadrupole	<ul style="list-style-type: none"> • Easily adapted to ESI • Low cost • Small size • Ease to switch between positive and negative ions 	<ul style="list-style-type: none"> • Limited mass range, up to 3000-4000 m/z • Relative low mass accuracy and resolution. Sensitivity and resolution are opposed using quadrupole analysers. • Poor adaptability to MALDI
Ion trap	<ul style="list-style-type: none"> • Easily adapted to MALDI and ESI • Excellent sensitivity • Ease to switch between positive and negative ions • Low cost • Small size. Simple design. 	<ul style="list-style-type: none"> • Limited mass range, up to 3000-4000 m/z • Relative low mass accuracy and resolution.

1 **Table S2.** Costs savings thank to MALDI-TOF MS by reduced need of conventional identification methods. Data derived from a 4 weeks study
 2 done in our laboratory, during which a total of 1214 microbial isolates were correctly identified at the species level by MALDI-TOF MS. These
 3 costs savings observed on a 4 weeks period were used to estimate the annual costs reduction.

Reagents	Identification	Number	Price/test (€)	Total (4 weeks) (€)	Total (extrapolation 1 year) (€)
Vitek GN ID card	Gram-negative bacteria	270	6.8	1836	23868
Vitek GP ID card	Gram-positive bacteria	146	6.1	890	11570
Rapid ID 32E	<i>Enterobacteriaceae</i>	16	5.3	84.8	1102.4
API NH	<i>Neisseria</i> and <i>Haemophilus</i> spp.	11	7.6	83.6	1086.8
Rapid ID 32 Strep	Streptococci	8	5.3	42.4	551.2
Vitek YST ID card	Yeasts	8	6.1	48.8	634.4
Rapid ID 32A	Anaerobes	1	5.3	5.3	68.9
Api coryne	<i>Corynebacterium</i> spp.	1	8.3	8.3	107.9
ID 32C	Yeasts	1	5.3	5.3	68.9
				Total: 3004.5	Total: 39058.5

4
 5 € , Euro. The prices were converted from Swiss Francs (CHF) to Euros according to the exchange rate of the 19th of April 2011.

1
2
3 1 **Figure S1.** Maintenance of MALDI-TOF mass spectrometer: (A) The MALDI-TOF
4
5
6 2 apparatus prior to disassembly. (B) The MALDI-TOF apparatus is completely opened during
7
8 3 maintenance to allow inspection and cleaning. (C) Please note the presence of dust particles in
9
10 4 the inner part of the MALDI-TOF mass spectrometer (arrow n° 1). (D) Dust may prevent
11
12 5 optimal tightness of the plastic joint (arrow n° 2) and this may lead to imperfect vacuum;
13
14
15 6 please note the presence of trace of carbonization at the entry of the acceleration tube (arrow
16
17 7 n° 3).
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1

Figure 1. Technical description of MALDI-TOF MS. The sample is mixed with a matrix on a conductive metal plate. After crystallisation of the matrix and microbial material, the metal plate is introduced in the mass spectrometer and is bombarded with brief laser pulses. The desorbed and ionized molecules are accelerated through an electrostatic field and ejected through a metal flight tube subjected to vacuum until they reach a detector, with smaller ions travelling faster than larger ions. Thus, bioanalytes separated according to their time of flight (TOF) create a mass spectrum that is composed by mass to charge ratio (m/z) peaks with varying intensities. A spectrum is thus a microbial signature that is compared to a database for the identification at the species or genus level.

192x289mm (300 x 300 DPI)




Figure 2. Intra-laboratory reproducibility tested by measuring the number of conserved peaks in two experimental settings. In the first setting, ethanol/formic acid extraction was applied on *E. coli* ATCC 25922 (A) or *S. aureus* ATCC 25923 (B) and 10 replicates of one extraction were spotted onto the MALDI-TOF microplate (1 μ l about 106 bacteria/ μ l). In the second setting, 10 independent extractions were done and one replicate of each extraction was spotted onto the MALDI-TOF microplate. After smoothing and baseline subtraction, the 100 highest peaks from each spot were selected and the number of time a given peak is present out of 10 times was determined for each peak in the two different settings for *E. coli* and *S. aureus*.
166x335mm (300 x 300 DPI)




Figure 3. The amount of material is a critical factor for accurate microbial identification by MALDI-TOF MS. (A) Spectral fingerprints obtained from various quantities (10^6 to 10^3) of *E. coli* ATCC 25922 grown on blood agar plates. The inoculums were prepared from a sample with a turbidity of 4.0 McFarland that was diluted to obtain the approximate quantity used for direct microplate deposition (10^6 to 10^3 bacteria per spot). Protein extraction was performed by directly mixing the samples with formic acid on microplate. The results show that the quality of the spectrum and thus the performance of identification are largely dependent on the sample amount spotted on the microplate. (B) Growth of *Staphylococcus epidermidis* on blood agar plates at 35°C in 5% CO_2 atmosphere after an incubation of 2, 4, 6, 8 hours, respectively. Usually, at least 6 hours incubation are required to get sufficient amount of material to obtain an efficient MALDI-TOF MS identification (C) Cumulative percentage of MALDI-TOF identification obtained from Gram-negative (*Escherichia coli* (13), *Pseudomonas putida* (2), *Klebsiella pneumoniae* (2), *Enterobacter cloacae* (1)) and Gram-positive (*Staphylococcus epidermidis* (13), *Staphylococcus aureus* (9), *Streptococcus pyogenes* (4), *Streptococcus*

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

pneumoniae (1), *Staphylococcus hominis* (1)) bacteria after short-time plating on agar during 2, 4, 6, 8 hours, respectively. The number of samples for each bacterial species analysed is indicated in brackets.
200x338mm (300 x 300 DPI)





Figure 4. Importance of the organization of a working day to optimize time to results. Each line represents a MALDI-TOF run, with the waiting time for equipment availability, the time required to prepare the target layout and the time of the MALDI-TOF running process. In this example of a working day, eight MALDI-TOF target plates have been used to analyse multiple clinical samples (ICU, S: intensive care unit and surgery (1 run); IM, P: internal medicine, pediatry and others (1 target plate); BC: blood cultures (4 runs); U: urine (2 runs)). Urgent samples such as blood cultures are directly processed while colonies identification from agar cultures are processed by batch. The processing of the samples is organized to guarantee the optimal use of the MALDI-TOF device during the working day.
89x48mm (300 x 300 DPI)



- score > 2.0 (accurate identification at the species level)
- 1.7 > score < 2.0 (moderate identification at the genus level)
- score < 1.7 (no identification)

Figure 5. *E. coli* identification yield in urine samples. Five ml of urine samples positive by microscopy were centrifuged to concentrate and collect the bacteria. The pellet was resuspended in 200 μ l water and subjected to protein extraction with ethanol and formic acid prior deposition on the microplate. The graph shows the identification yield according to the bacterial load per ml. 95x82mm (300 x 300 DPI)




Figure 6. Importance of the maintenance and quality controls of the MALDI-TOF device demonstrated by a follow-up of the temporal reproducibility. (A) Spectral fingerprint of *S. aureus* quality controls during a 10 weeks control period. (B) Percentage of conserved peaks during a 10 weeks control period. *E. coli* and *S. aureus* quality controls fingerprints were compared to a set of conserved peaks (81 and 80 respectively). The poor performance observed during week 1 to 3 was likely caused by a problem of inadequate sample deposition on the MALDI-TOF MS microplates. 229x334mm (300 x 300 DPI)




Figure 7. Quality control for MALDI-TOF mass spectrometry. (A) Presence of residual materials on some wells (especially C4, E3 and E4, indicated by white arrows) of a MALDI-TOF microplate after a routine wash, highlighting the importance of careful wash after each usage; (B) mass spectra obtained with the Bruker BST control, that consists in lyophilized *E. coli* spiked with RNase A (black arrow at a m/z of 13683) and myoglobin (white arrow at a m/z of 16952); in the lower part of the panel, the list of the eight proteins that should be present to validate the run and their expected and observed m/z values.

169x269mm (300 x 300 DPI)




Figure S1. Maintenance of MALDI-TOF mass spectrometer: (A) The MALDI-TOF apparatus prior to disassembly. (B) The MALDI-TOF apparatus is completely opened during maintenance to allow inspection and cleaning. (C) Please note the presence of dust particles in the inner part of the MALDI-TOF mass spectrometer (arrow n° 1). (D) Dust may prevent optimal tightness of the plastic joint (arrow n° 2) and this may lead to imperfect vacuum; please note the presence of trace of carbonization at the entry of the acceleration tube (arrow n° 3).
132x204mm (300 x 300 DPI)